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1. Introduction 
 
1.1. Telomeres structure and function 
 
Telomeres are terminal protein-DNA complexes forming capping structures that function to 
stabilize chromosomal ends and prevent them from being recognized by the cell as DNA 
double strand breaks. Functional telomeres require sufficient numbers of telomeric DNA 
repeats, as well as the proper repertoire and amounts of telomere associated proteins; mutation 
or loss of either can lead to “uncapping” and telomere dysfunction (Saldanha et al. 2003, 
Karlseder 2003). In particular, mammalian telomeres consist of tandem repeats of the six 
nucleotides TTAGGG, which are repeated for 5–25 kilobase pairs in length 5’ to 3’ toward 
the chromosome end (de Lange et al. 1990). Several recent studies have suggested that the 
structure of the ends of telomeres may be more complex than originally thought. Griffith and 
colleagues have found that telomeres do not end in a linear manner (Griffith et al. 1999). 
Instead, the end of the telomere can form a loop structure with the 3’ G-rich strand (referred 
to as the T-loop), invading the duplex telomeric repeats and forming a displacement loop (D-
loop, Fig. 1.1-1). Telomere-associated proteins may facilitate the formation and maintenance 
of both the T- and D-loops, suggesting the presence of a large DNA-protein structure at the 
end of each chromosome. In addition, most human telomeres appear to terminate in a single-
stranded 3’ GT-rich overhang, which is thought to play an important role in telomere structure 
and function (Wright et al. 1997). The atomic-level structural details of the loop are not 
known, but the 3’ overhang must be incorporated in some manner into the terminal part of the 
double-stranded telomeric region. Fig. 1.1-2 shows the T-loop/D-loop with the array of 
telomeric proteins that have been identified to date as having direct or indirect association 
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Fig. 1.1-1: Schematic representation of the T-loop/D-loop model for human 
telomeres capping structure (Rezler et al. 2003). 
Fig. 1.1-2: The end of the human chromosome: the telomeric T-loop/D-loop 
model, showing known telomeric proteins (Neidle et al. 2003). 
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with telomeric DNA (Neidle et al. 2003). TRF1 and TRF2 are both associated with and 
critical to the formation of the T-loop and D-loop structures. They bind specifically to 
telomeric double-stranded DNA and the loss of functional TRF2 in human cells results in the 
generation of end-to-end chromosomal fusions (Stansel et al. 2001). Of particular interest is 
the human protein hPot1, which has been shown to specifically bind to the single-stranded 3’ 
overhang of the human telomeric sequence and has been identified in many species, playing 
an as yet undetermined role in the capping of chromosomes. However, deletion of the pot1+ 
gene results in the loss of telomeric DNA and end-to-end chromosomal fusions (Baumann et 
al. 2001). 
In addition to protecting chromosomes from end-to-end fusion, telomeres are also thought to 
avoid the loss of DNA at the end of each chromosome upon the completion of DNA 
replication. In fact, dividing cells have been shown to undergo a progressive loss of 25–200 
DNA base pairs following each cell division (Harley et al. 1990). This loss of telomeric DNA 
is largely due to the “end replication problem” (Fig. 1.1-3), which refers to the inability of the 
DNA replication machinery to copy the final few base pairs of the lagging strand during DNA 
synthesis (Watson 1972). Another possible cause for loss of telomeric sequence is by a 5’ to 
3’ exonuclease activity that recesses the telomeric CA-rich strand (Makarov et al. 1997). 
Because the telomere consists of a repetitive DNA sequence, its loss is thought to be less 
important to the cell than the loss of critical gene encoding sequences that may be near the 
end of a chromosome; therefore, repetitive telomeric sequences protect the cell from the loss 
of more critical gene encoding sequences (Rezler et al. 2003). 
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Fig. 1.1-3: End replication problem. DNA replication starts by the unwinding of 
double stranded DNA at the origin of replication. Synthesis of the new 
strands of DNA proceeds in the 5′ to 3′ direction. The leading strand is 
continuous, but the lagging strand is synthesized as a series of short 
segments of DNA (Okazaki fragments) onto the ends of RNA primers 
(top). The RNA primers are removed and DNA polymerase fills in the 
gaps, which are then ligated (not shown). The extreme 3′ end is not 
replicated leading to DNA loss and the ‘end replication problem’ 
(bottom, White et al. 2001). 
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1.2. G-quadruplex DNA structures 
 
 Most of cellular DNA is known to be double stranded; several duplex DNA structures have 
been known so far (Watson et al. 1987, Fig. 1.2-1). The single-stranded guanine-rich 
sequences of telomeric DNAs can assume non canonical structures, referred to as G-
quadruplex (Neidle et al. 2003). They are four-helices structures based on the G-quartet, in 
which four guanine bases associate with each other in a stable Hoogsteen hydrogen-bonded 
arrangement (Fig. 1.2-2). This arrangement, necessarily involving four DNA strands, can 
result in a variety of four-stranded G-quadruplex structural types, whose features depend on 
several factors, such as the number of separate strands, the pattern of strand orientation, the 
nature of the loops connecting the G-tetrads, the nature and concentration of monovalent 
cations stabilizing the structure and the glycosidic bond conformation (Fig. 1.2-2, Simonsson 
2001, Williamson 1994). Alkali metal ions (typically sodium or potassium) are necessary for 
quadruplex stability, because they coordinate the O6 guanine atoms in a G-quartet (Fig. 1.2-
3). In general, potassium ions, at physiological concentrations, provide optimal stability. 
Different metal ions can induce conformational change, which, depending on the quadruplex, 
can be profound, as in the case of the intramolecular quadruplex formed by the four-repeat 
sequence d[AGGG(TTAGGG)3]. The NMR structure of the sodium form of the 
intramolecular quadruplex formed by (almost) four repeats of d(TTAGGG) in the 22-mer 
sequence d[AGGG(TTAGGG)3] was reported several years ago (Wang et al. 1993). It 
comprises a core of three G-quartets held together by strands in alternating orientations (Fig. 
1.2-4(c,f)). This results in two lateral and one diagonal d(TTA) loop at the G-quartet ends. 
The crystal structure of the potassium form, crystallised under approximately physiological 
ionic conditions, shows a strikingly distinct arrangement, with all four strands parallel (Fig. 
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Fig. 1.2-1: A, B and Z-DNA double helix structures. Bases are red, while 
sugar-phosphate backbone is grey (Watson et al. 1987). 
 
A-DNA 
B-DNA 
Z-DNA 
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Fig. 1.2-2: The fundamental features of G-quadruplexes: the G-tetrad, strand 
orientations and glycosidic bond conformations. (a) The arrangement of 
hydrogen bonds between guanines in a G-tetrad. (b) The possible 
orientations of four DNA strands (Neidle et al. 2003). (c) Syn and anti 
conformations of the glycosidic bond connecting the guanine base to 
the sugar-phosphate backbone (Williamson 1994).  
 
(c) 
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Fig. 1.2-3: Stabilization of G-quadruplex by monovalent cations. Alkali metal ions coordinate 
the O6 guanine atoms of two adjacent G-quartets (top, Williamson 1993). X-ray 
derived G-quadruplex structure for d(TG4T), in which sodium ions between G-
quartets are shown as yellow spheres (bottom, Rhodes et al. 1995). 
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1.2-4(d,g), Fig. 1.2-5, Parkinson et al. 2002). This results in all three d(TTA) loops being 
external to the core and positioned alongside the grooves, rather than at the ends of the G-
quartet stack. On the contrary, in the case of d(GGGGTTTTGGGG) from the telomeric 
sequence of Oxytricha nova, changes in alkali metal ions do not effect conformational change. 
In fact, both potassium and sodium forms show a G-quadruplex structure with 
parallel/antiparallel strand orientations and diagonal loops formed from opposite strands (Fig, 
1.2-4(a), Haider et al. 2002). On the other hand, the sequence with one fewer 3’ guanine, 
d(GGGGTTTTGGG), also forms a dimeric quadruplex, but with a distinctive, asymmetric 
fold involving just three stacked G-quartets, rather than the four in the d(GGGGTTTTGGGG) 
structure. The two guanines not involved in the G-quartets are unpaired and are involved in 
stacking interactions with the G-quartet face and a thymine in the adjacent T4 loop (Fig. 1.2-
4(b), Crnugelj et al. 2002). This shows that even a minor sequence difference can result in 
major structural changes to the folding of G-quadruplex (Neidle et al. 2003).  
The complementary cytosine-rich strand, in duplex telomeric DNA or other non-telomeric G-
rich sequences of the genome, can also form non-standard structures, built upon the i-motif. 
This category of four-stranded structure is only stable at low pH, as it involves C+•C base 
pairs. The NMR structure of a 22-mer cytosine-rich telomere sequence (complementary to the 
guanine-rich d[AG3(T2AG3)3]) has been reported (Phan et al. 2000). It shows an 
intramolecularly folded structure with six intercalated C+•C base pairs (the i-motif part, Fig. 
1.2-6) linked by three d(AAT) hairpin-type loops (Fig. 1.2-4(e)).  
G-quadruplexes are usually thought to arise only from the folding of single-stranded telomeric 
DNA, that is, the 3’ overhang. However, they may also be formed from duplex telomeric 
DNA under appropriate ionic and pH conditions (Phan et al. 2002), as well as by the 
influence of appropriate proteins or ligands. This possibility has been demonstrated in a 
sequence analogous to that of the telomere, the guanine-rich nuclease hypersensitive promoter 
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Fig. 1.2-4: Ribbon diagrams of various telomeric DNA quadruplex structures. (a) d(G4T4G4) 
from Oxytricha (Haider et al. 2002). (b) d(G4T4G3) (Crnugelj et al. 2002). (c) 
d[AG3(T2AG3)3] in Na+ solution (Wang et al. 1993). (d) d[AG3(T2AG3)3] with K+ 
in the crystal (Parkinson et al. 2002). (e) d(C2AT2C2AT2C2T3C2) in solution - the 
i-motif (Phan et al. 2000). (f,g) Representations of the folds in structures (c,d), 
respectively (Neidle et al. 2003). 
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Fig. 1.2-6:  C•C+ base pair and schematic representation of the i-motif (Fedoroff et al. 2000). 
Fig. 1.2-5:  Overall folding topology of the 22-mer intramolecular G-quadruplex formed by 
the sequence d[AGGG(TTTAGGG)3]. (a) Stick representation coloured by atom 
type and viewed on the 5' face. The central potassium counter ion is coordinated 
in a bipyramidyl antiprismatic arrangement by the electronegative carbonyl 
groups of guanine O6. (b) View from the 3' end of the quadruplex looking down 
the helical axis with the phosphate sugar backbone drawn as a grey ribbon 
showing 5'-to-3' directionality. Guanines are green, thymines blue, and adenines 
red. (c) A representative part of the structure around the extended TTA loop 
region abutting the sides of the G-quadruplex. Overlaid is a A-weighted map 
using data at 10–2.1 Å resolution contoured at 1.8  . (d) Side view of the 
quadruplex highlighting its disc-like shape and positioning of the 3' and 5' 
strand ends. (e) Space-filling van der Waals contoured representation, coloured 
by charge, with red surfaces representing regions of negative charge (Parkinson 
et al. 2002). 
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sequence of the c-myc oncogene. The formation of a quadruplex structure, driven by the 
presence of the quadruplex-binding porphyrin ligand TMPy4, was observed (par. 1.5, 
Siddiqui-Jain et al. 2002).  
The c-myc study has also answered the question of the biological existence of quadruplexes, 
at least in the special context of the c-myc promoter sequence. Recently, the existence of 
telomeric quadruplexes has been demonstrated in the macronuclei of the ciliate Stylonychia 
lemnae using specific antibodies generated against T4G4 sequences (Schaffitzel et al. 2001). 
An analogous study has not yet been reported for human telomeres, although quadruplex-type 
structures may be involved in telomere loop regions (par. 1.1) and several telomere-associated 
proteins, such as Cdc13, do bind quadruplex DNA with high affinity (Neidle et al. 2003).  
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1.3. Telomerase: its role in cellular senescence and cancer 
 
Telomere maintenance is necessary for long-term cell proliferation. In the absence of a 
specific replication machinery at the telomere ends gradual sequence loss due to incomplete 
replication of the lagging strand would eventually lead to critically short telomeres and 
trimming of essential chromosomal sequences (Allsopp et al. 1995). The mechanism whereby 
cells count divisions uses the gradual erosion of telomeres, which ultimately triggers 
replicative senescence in many cell types. In order to compensate for this loss, different 
mechanisms for the addition of new telomere sequences have evolved. In humans, telomere 
maintenance is mainly performed by a specific reverse transcriptase, telomerase (Mergny et 
al. 2002). Human telomerase is a ribonucleoprotein (Morin 1989) composed of a catalytic 
subunit, hTERT (Nakamura et al. 1997), and a 451 nt long RNA (hTR; also known as hTER 
or hTERC) (Feng et al. 1995), which contains an 11bp sequence that acts as the template on 
which telomeric repeats are added to the chromosome. Telomerase is active in the germline, 
as well as some stem cells, but is inactive in most somatic cells (Kim et al. 1994). 
Furthermore, recent key experiments demonstrated that: (i) telomerase is sufficient for 
immortalisation of many cell types (Bodnar et al. 1998) and sufficient to allow transformed 
cells to escape from crisis (Halvorsen et al. 1999); (ii) inhibition of telomerase limits the 
growth of human cancer cells (Hahn et al. 1999); (iii) ectopic expression of the telomerase 
catalytic subunit (hTERT; also known as hEST2 or hTRT) in combination with several 
oncogenes results in direct tumourigenic conversion of normal human epithelial and fibroblast 
cells. All these results point to a key role of telomerase in the tumourigenic process. 
Mutations leading to reactivation or up-regulation of the enzyme may represent a required 
event in the multistep development of many cancers (Mergny et al. 2002). In some cases 
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(notably neuroblastomas, gastric and breast tumours), higher levels of telomerase activity are 
associated with poor prognosis, showing that telomerase could be used as a predictive marker 
(Hiyama et al. 2003).  
In vitro reconstitution of human telomerase is possible in cell extracts with two partners, the 
template RNA component hTR and the catalytic protein subunit hTERT, but several other 
proteins are associated with hTERT or hTR and facilitate their folding or assembly (Fig. 1.3-
1, Mergny et al. 2002). A unique feature of telomerase is its ability to synthesize long 
stretches of DNA (often >100 nt) despite the minimal lengths of the templating RNA 
segment. This ability to synthesize DNA processively depends on two types of movement 
(Fig. 1.3-2): simultaneous translocation of the RNA–DNA duplex away from the active site 
following each nucleotide addition (type I) and translocation of the 3’ end of the DNA 
substrate relative to the RNA template (type II). The latter translocation reaction enables 
telomerase to repeatedly utilize the same set of templating residues for DNA synthesis, thus 
generating long extension products. The propensity to carry out type I and type II 
translocation has been referred to as nucleotide addition and repeat addition processivity, 
respectively (Lue 2004). 
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Fig. 1.3-1: Telomerase components. Telomerase is composed of two major components: the catalytic subunit (hTERT) and the 
template RNA (hTR). Several proteins are associated with hTERT or hTR and facilitate their folding or assembly. 
Many different proteins interact with telomeric DNA and participate in telomerase recruitment (Mergny et al. 2002). 
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Fig. 1.3-2: The addition of telomeric repeats. Telomerase adds hexameric 
TTAGGG repeats by attaching to the end of the chromosome and 
then utilizing its internal template to specify the sequence of 
added nucleotides. As evidenced by telomerase repeat addition 
processivity, it then is able to reposition downstream and re-
anchor its template for the addition of more telomeric repeats 
(White et al. 2001). 
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1.4. Telomerase inhibitors 
 
Telomerase properties described in the previous paragraph make this enzyme a target not only 
for cancer diagnosis but also for the development of novel therapeutic agents. The expected 
effects of telomerase inhibition on cancer cells as well as telomerase-positive normal cells are 
illustrated in Fig. 1.4-1 (White et al. 2001). The classical model for inhibition of telomere 
maintenance and telomerase activity as a potential anticancer therapy suggests that the 
inhibition of telomerase in tumour cells will initially only result in telomere shortening at each 
successive round of replication. This will eventually drive telomerase-positive tumour cells to 
senescence prior to normal (and germ line) cells, as a consequence of the significantly shorter 
length of telomeric DNA in the former cells (Incles et al. 2003).  
There are some potential concerns that have been raised about telomerase as an anticancer 
target. First, with many (but not all) telomerase therapeutic approaches, one expects there will 
be a lag phase between the time telomerase is inhibited and the time telomeres of the cancer 
cells will have shortened sufficiently to produce detrimental effects on cellular proliferation. 
The exact number of nucleotides lost per round of replication in a typical tumour cell line is 
not generally known, but is likely to be around 50–200. So, for telomeres with an average 
length of 5 kb, about 50 rounds of replication will have to occur before the onset of 
senescence and subsequent apoptosis, assuming that telomeres must be completely eroded 
before observing an effect. This implies an extensive lag time before the positive effects of 
the drug can occur. For a tumour cell that has a 24-hour doubling time, there is the theoretical 
possibility that tumour growth will rapidly overtake telomere-shortening effects (Neidle et al. 
2002). If this is correct, it would suggest that telomerase inhibitors might be most effective in 
combinations with other conventional or experimental cancer treatments (Fig. 1.4-2). It is 
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Fig. 1.4-1: Effects of telomerase inhibition on the telomere lengths and 
proliferative capacity of both cancer cells and telomerase positive 
normal human somatic cells and germ line cells. (White et al. 
2001). 
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Fig. 1.4-2: Telomerase inhibitors and conventional therapies (Shay et al. 2002). A telomerase inhibitor used as a single agent will 
progressively reduce telomere length, but there is an expected time delay until cell death. Conventional cytoxic therapies will 
initially reduce tumour burden but not affect telomere length. Combinations of conventional therapies with telomerase 
inhibitors would be predicted to both reduce tumour burden and shorten telomeres, potentially preventing or delaying tumour 
recurrences. 
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possible that in primary human tumours there will be some very short telomeres in most cells 
and that the lag phase before telomerase inhibitors produce proliferative deficiencies in vivo 
may be more rapid than that observed in tumour cell line preclinical models (Shay et al. 
2002). 
Another issue that has been raised about telomerase inhibitors is that alternative mechanisms 
for telomere maintenance (referred to as ALT, alternative lengthening of telomeres) have been 
reported in other organisms, in experimentally derived human immortalized cell lines, and in 
some rare human cancers (Lundblad 2002). Proposed ALT mechanisms involve telomeres 
recombination (Fig. 1.4-3, Wang et al. 1990, Reddel et al. 1997), but recent findings about t-
loops (par. 1.1) could suggest analogous mechanisms inside one telomere terminus. 
Telomerase inhibitors might thus result in the emergence of drug-resistant telomerase-
independent cancer cells. While this is certainly a possibility, there have been no published 
reports of telomerase-positive human tumour cells being experimentally converted to a 
telomerase-independent pathway using telomerase inhibitors (Shay et al. 2002). 
Telomerase is unusual among cancer molecular targets because a large body of outstanding 
basic science in telomere biology has preceded development of effective lead compounds, 
allowing potential problems to be anticipated before evidence of efficacy in model systems is 
in hand, exactly the opposite of the situation faced during most drug development. Even 
though telomerase does not cause cancer and its role in cancer is most probably permissive, 
cancer therapy directed at telomerase has advanced in some instances to clinical trials to 
validate safety and specificity (Shay et al. 2002). The telomerase holoenzyme complex 
presents multiple potential sites for the development of inhibitors. These include the 
functional RNA or hTR, the catalytic reverse transcriptase subunit hTERT, the primer 
anchoring site, holoenzyme assembly and the factors involved in recruiting telomerase to the 
telomere (White et al. 2001, Fig. 1.4-4).  
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Fig. 1.4-3: A model for recombination-mediated lengthening of telomeres (Wang et al. 
1990). (a) When a telomere becomes critically short it may be interpreted by 
the cell as a double-strand break (DSB). (b) The DSB repair enzymes then 
mediate invasion by a single-stranded 3´ end of the short telomere between the 
strands of a longer telomere. DNA polymerase may then extend the short 
strand, using the long strand as the template. (c) The crossed-over strands may 
then be subject to cleavage by a nuclease (→) followed by ligation, resulting in 
recombinant DNA molecules. (d) Alternatively, the structure shown in (b) may 
be resolved by unwinding of the newly formed helix and rewinding, resulting 
in non-recombinant molecules. In either case, the staggered annealing of 
repeats in the short and long telomeres results in net telomere elongation 
(Reddel et al. 1997). 
 
d 
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Fig. 1.4-4: Strategies for telomerase inhibition. Possible pathways of pharmacological inhibition of telomerase: targeting of the catalytic 
subunit; antisense or ribozyme strategies against hTR; targeting telomeric DNA (Mergny et al. 2002). 
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Antisense oligodeoxynucleotides (ODN) are an area of heightened interest in the field of 
telomerase inhibition. These drugs consist of short stretches of DNA that are complementary 
to a target RNA. The mechanism of action for most applications is to hybridize to their 
complementary RNA by Watson–Crick base pairing and inhibit the translation of the RNA by 
a passive and/or active mechanism. The passive inhibition occurs simply by the competitive 
binding of the ODN to the mRNA, whereas the active mechanism recruits RNaseH to degrade 
the mRNA once the RNA–ODN hybridization occurs (Galderisi et al. 1999). Telomerase 
presents itself as an intriguing target for these drugs because it possesses a functional RNA 
component as part of its structure. The template region of hTR must be exposed to add new 
telomeric repeats onto the chromosome, making this an accessible target for the ODN. Thus, 
rather than using ODNs to inhibit translation, ODNs directed against the hTR template are 
designed to directly inhibit telomerase activity. ODNs present several problems in drug 
development, mainly related to cellular delivery and degradation by a variety of exo- and 
endonucleases. Chemical modifications to the ODNs and transfecting agents have been 
implemented to reduce these problems. A variety of studies have been published on the 
inhibition of telomerase using antisense approaches directed both at the template and at non-
template regions of hTR (White et al. 2001). The first report was by Feng et al. (1995); since 
that first study there have been many reports on antisense ODN inhibitors of telomerase. 
Many of these have reported a reduction in telomerase activity in cancer cells treated in 
culture. Another class of oligonucleotides being studied are peptide nucleic acids (PNAs). 
PNAs are analogues of RNA and DNA, in which the pentose-phosphate backbone is replaced 
by an oligomer of N-(2-aminoethyl)glycine, making them resistant to degradation by endo- 
and exonucleases. Although the pharmacokinetics and uptake of these drugs in vivo is largely 
unknown, they present an exciting new class of oligonucleotide agents (White et al. 2001). 
Hammerhead ribozymes are small RNA molecules that possess specific endoribonuclease 
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activity. They consist of a catalytic core flanked by anti-sense sequences that function in the 
recognition of the target site. This strategy for telomerase inhibition might prove to be a 
useful tool if investigators are able to demonstrate the expected effects on telomere biology 
with specific targeting of the telomerase RNA (White et al. 2001). 
Another approach to telomerase inhibition is based on dominant negative hTERT constructs 
(mutants that are catalytically inactive but still able to bind and sequester hTR). They 
effectively inhibit telomerase both in vitro and in vivo, as demonstrated by introducing cDNA 
that contains point mutations in the reverse transcriptase motifs of hTERT into human tumour 
cell lines (Zhang et al. 1999). Because of its RNA-dependent DNA polymerase activity, 
telomerase could be in principle inhibited by classical reverse transcriptase inhibitors (RTIs), 
such as 3′-azido-3′-deoxythymidine (AZT). They were demonstrated to cause telomerase 
inhibition and slowed growth of cells in culture; however, they have not shown telomere 
erosion or eventual growth arrest of the cells after prolonged exposure (Strahl et al. 1996). A 
plausible explanation might be that the RTIs have a toxic effect on the cells, perhaps by 
inhibiting mitochondrial DNA replication leading to the observed reduction in telomerase 
activity, which is dose dependent (White et al. 2001). 
Recently, there has been exciting work in the field of antigen-specific immune responses in 
tumour cells. Telomerase is present in the majority of human tumours and is, therefore, a 
good candidate as a universal tumour-associated antigen (White et al. 2001). 
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1.5. Molecules able to induce and stabilize G-quadruplex 
structures as telomerase inhibitors 
 
Inhibition of telomerase can be achieved by sequestration of the primer (the single-stranded 
telomeric end) required for the reverse transcriptase activity of this enzyme, by G-quadruplex 
formation (Fig. 1.5-1, Mergny et al. 1998). This was first demonstrated by showing that K+ 
inhibited telomere activity, presumably by facilitation of folding of the single-stranded 
telomeric DNA into a G-quadruplex structure (Fig. 1.5-2, Zahler et al. 1991). Three 
approaches are being followed in this rapidly expanding field (Neidle et al. 2002), and have 
been aided by the development of high-throughput G-quadruplex binding assays (FRET 
assays, par. 3.3.c). (i) Rational structure-based design: molecular models based on several 
quadruplex systems, in particular those derived from the NMR (Wang et al. 1993) and X-ray 
(Parkinson et al. 2002) models for the d[AGGG(TTAGGG)3] intramolecular G-quadruplexes, 
have been used in structure-based design strategies (Fig. 1.5-3, Harrison et al. 1999). (ii) 
Computational approaches: in silico screening for quadruplex-binding compounds has 
produced several successes, leading to the discoveries of several G-quadruplex interactive 
compounds, among which the perylene derivative PIPER (par. 1.6, Fedoroff et al. 1998); this 
approach does require care in choosing a library of compounds that has some characteristics 
suitable for G-quadruplex high-affinity binding (Neidle et al. 2002). (iii) Conventional 
screening: some success in identifying G-quadruplex ligands as telomerase inhibitors has 
been achieved by screening existing chemical libraries (Chen et al. 1996) in combination with 
combinatorial approaches (Riou et al. 2002); screening of the metabolites of the 
microorganism Streptomyces anulatus identified an exceptionally potent inhibitor, the eight-
ring cyclic molecule telomestatin (Fig. 1.5-4, Shin-ya et al. 2002).  
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Fig. 1.5-2:  Model for the effect of primer structure on telomerase action (Zahler et al. 1991). 
The most stable folded form, represented as a G-quadruplex structure, is unable to 
bind to the RNA template of telomerase. The folded primer is in equilibrium with 
the unfolded form, which is able to bind the telomerase and is elongated by the 
addition of nucleotides. Once the end of the internal RNA template is reached, a 
translocation step must occur before the next repeat is synthesized.  
Fig. 1.5-1: Schematic of telomerase inhibition being produced by folding of the 3' end 
telomere primer strand into a G-quadruplex structure, which is stabilized by 
ligand stacking onto the G-quartet end. This folding then inhibits further 
hybridization of the primer with the hTR template from taking place during 
subsequent cycles of telomere extension. (Mergny et al. 1998). 
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Fig. 1.5-3: Structure-based design of G-quadruplex ligands: views from molecular 
modeling of several inhibitors that interact with the G-quartet surface of a 
quadruplex. (a) A di-substituted anthraquinone, (b) the PIPER molecule, (c) a 
tetrapyridyl-porphyrin and (d) the telomestatin molecule. Differences in 
ligand–G-quartet overlap are clearly apparent (Neidle et al. 2002).  
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All these different approaches led to a number of different classes of molecules that have been 
shown to be able to induce and/or stabilize G-quadruplex DNA structures and to inhibit 
human telomerase (Fig. 1.5-4). Almost all of the several hundred G-quadruplex ligands that 
have been discovered so far share the common structural feature of an extended planar 
aromatic chromophore, in common with conventional duplex DNA-intercalating drugs 
(Neidle et al. 2002). An early proposal was that these compounds could similarly intercalate, 
but in between pairs of stacked G-quartets. However, molecular-modelling studies, together 
with interpretation of low-angle diffraction data from a crystal of a parallel-quadruplex 
complex, indicated an alternative model, in which the ligand is stacked onto the ends of the 
G-quartets (Read et al. 2000). The unfavourable energetics and slow dissociation kinetics of 
G-quartet destacking also favour this structural model, which has a chromophore that is 
involved in pi-pi interactions with the terminus of the G-quartet system. This external model is 
supported by several NMR studies (Fedoroff et al. 1998, Han et al. 2001, Kim et al. 2002), as 
well as by the stoichiometry found from solution binding studies (Read et al. 2001). 
Molecular modelling indicates that ligand side chains could be positioned in the grooves of a 
quadruplex, stabilized by appropriate non-bonded interactions (Read et al. 1999, Read et al. 
2001), and that these interactions can significantly contribute to overall stability and 
selectivity (Neidle et al. 2002). 
These design criteria are evident in the development of a number of promising compound 
series. For example, disubstituted amidoanthraquinones and amidoacridines (Fig. 1.5-4) 
inhibit telomerase in the low-micromolar range but exhibit equipotent cytotoxicity so that the 
IC50 (acute cellular toxicity) value is not much higher than the telEC50 (telomerase inhibitory 
ability) value (Incles et al. 2003). In contrast, trisubstituted anilino-acridines such as BRACO-
19 (Cancer Research Technology, Fig. 1.5-4) demonstrate up to two orders of magnitude 
improvement in their telEC50 values while exhibiting a parallel improvement in cytotoxicity. 
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Fig. 1.5-4: Structures of  representative G-quadruplex interactive compounds used as 
telomerase inhibitors (Neidle et al. 2002).  
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Both these effects are believed to be due to the increased selectivity of the compounds for G-
quadruplex over duplex DNA that results from the incorporation of the third side chain (Read 
et al. 2001) and its recognition of the unique groove structural features of the human 
intramolecular quadruplex (Fig. 1.5-5). This is reflected in a 10-fold increase in G-quadruplex 
affinity compared to disubstituted acridines coupled with a reduction in duplex DNA affinity 
as a result of steric hindrance to duplex binding. Although the aromatic scaffold may drive the 
initial DNA recognition due to stacking, the interplay between peripheral moieties and other 
groups on the DNA (in particular, the negatively charged phosphates of the TTA loops and 
grooves) may be just as important and can lead to major variations in terms of both enzyme 
inhibition and selectivity (Incles et al. 2003). 
Extension of the acridine scaffold has led to the development of several potent compounds. 
As the surface presented for pi-pi stacking by the G-quartet is significantly larger than that in 
the case of a simple duplex base pair, these compounds are expected to demonstrate some 
preference for G-quartets. Good results have been achieved with dibenzophenanthrolines (Fig. 
1.5-4, Read et al. 2001). A different approach has also been reported for 2,7-disubstituted 
acridines, in which the joining of two such groups leads to a significant increase in the telEC50 
value of the resulting acridine dimer (Fig. 1.5-6), presumably due to the increased interactions 
of two acridine groups with the exposed guanines of the G-tetrad (Alberti et al. 2001). Also 
dimerization of dibenzophenanthrolines (Fig. 1.5-6) led to large improvements in potency, 
with telEC50 values of 0.13 µM, with improved telomerase inhibitory properties and G-
quadruplex stabilization (Teulade-Fichou et al. 2003). 
Unlike other telomerase inhibitors, G-quadruplex-interactive compounds would be expected 
to affect cells that maintain telomeres by telomerase-dependent as well as telomerase-
independent mechanisms because the latter involve recombination mechanisms quite possibly 
involving G-quadruplex structures (par. 1.4, Wang et al. 1990, Reddel et al. 1997). Moreover, 
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Fig. 1.5-5: The basis for the rational design of second-generation acridine inhibitors, 
showing how a third substituent on an acridine skeleton (yellow) can interact 
in a third groove of a quadruplex. Such a molecule has inherent selectivity 
over DNA-duplex-binding molecules, as the two grooves of B-form duplex 
DNA cannot readily accommodate tri-substitution. The views are down onto 
the plane of a G-quartet (Neidle et al. 2002). 
 
Fig. 1.5-6: Dimerization of G-quadruplex interactive compounds led to increased 
telomerase inhibition (Incles et al. 2003).  
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an altered telomere state may be a more important consequence than critical telomere 
shortening (Karlseder et al. 2002). Thus, sequestration of telomere ends by stabilization of G-
quadruplex structures may lead to chromosome instability in presenescence cells. In 
particular, in cancer cells, where it is necessary to add telomeric sequences via a telomerase-
dependent or telomerase-independent mechanism, the single-stranded DNA template becomes 
exposed in the uncapped state, and if either telomerase is deficient or G-quadruplex-
interactive compounds are present, which facilitate folding of the G-quadruplex, irreversible 
uncapped telomeric ends and chromosome end-to-end fusion may result (Rezler et al. 2003). 
This finding has important implications for the future clinical utility of G-quadruplex 
inhibitors, and clearly indicates that they might not require an extended time period before 
effects become significant (Fig. 1.5-7, Neidle et al. 2002).  
The formation of G-quadruplex structures in regions other than telomeres, for example in the 
promoter region of c-myc, may also lead to effects on telomerase because c-myc controls 
hTERT. Indeed, the G-quadruplex-interactive compound TMPyP4 (Fig. 1.5-4), is able to 
down-regulate c-myc and hTERT (Siddiqui-Jain et al. 2002). The case of this porphyrin 
derivative is particularly interesting, since it was shown also to be able to promote the 
formation of the i-motif DNA structure in the cytosine-rich telomeric strand, complementary 
to the guanine-rich sequence (par. 1.2, Fedoroff et al. 2000). This study raises the intriguing 
possibility that TMPyP4 can trigger the formation of unusual DNA structures in both strands 
of the telomeres, which may in turn explain the recently documented biological effects of 
TMPyP4 in cancer cells (Grand et al. 2002). 
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Fig. 1.5-7: Schematic of the sequence of events that can take place after quadruplex-
induced telomerase inhibition, with two pathways to selective cell death 
being shown, dependent on telomere length (Neidle et al. 2002). 
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1.6. Previous studies on perylene diimides and berberine 
 
1.6.a. Perylene diimides 
 
 
 
 
 
 
 
 
 
 
 
PIPER (N,N’-bis[2-(1-piperidino)ethyl]-3,4,9,10-perylenetetracarboxylic diimide) was 
reported to inhibit telomerase and bind to a G-quadruplex structure for the first time in 1998 
in an NMR study by Hurley and coworkers (Fedoroff et al. 1998). According to the NMR-
based models, the ligand molecule does not intercalate within the G-quadruplex itself but 
rather stacks on the surface of the 3’-terminal G-tetrad (Fig. 1.6-1). This binding mode can be 
classified as a “threading intercalation”, with a fast structural transition between the two 
orthogonal drug orientations (Fig. 1.6-2). The highly dynamic nature of the ligand-quadruplex 
complex makes the precise structural characterization extremely difficult (Fedoroff et al. 
1998). Successively, PIPER was reported as the first example of a small ligand behaving as a 
driver in the assembly of G-quadruplex structures (Han et al. 1999). The authors of this paper 
demonstrate by means of gel-shift experiments that PIPER can dramatically accelerate the 
association of a DNA oligomer containing two tandem repeats of the human telomeric 
sequence (TTAGGG) into di- and tetrameric G-quadruplexes. In so doing, PIPER alters the 
oligomer dimerization kinetics from second to first order. The most likely pathways for the 
assembly of various dimeric and tetrameric G-quadruplex structures invoke both 
isomerization and association reactions (Fig. 1.6-3). Without external factors affecting 
NN
N+
N+
O
O
O
O
H
H
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Fig. 1.6-1: NMR-based models of the 2:1 [dTTAGGG]4-PIPER complex (left) and of 
the 1:1 [dTAGGGTTA]4-PIPER complex (right). The ligand molecule is in 
green or blue, the DNA guanine residues are in yellow, and the adenine 
and thymine residues are in purple (Fedoroff et al. 1998). 
Fig. 1.6-2: NMR studies suggest a fast structural transition between the two possible 
orthogonal drug orientations (Fedoroff et al. 1998). 
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Fig. 1.6-4: Conversion of duplex and single-stranded G-rich oligonucleotides to G-
quadruplex under conditions of limiting (upper pathway) and excess (lower 
pathway) PIPER (Rangan et al. 2001). 
Fig. 1.6-3: Several dimeric G-quadruplex isomers can form via dimerization of guanine-
guanine hairpins or folding of a guanine-guanine duplex (Han et al. 1999). 
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oligonucleotide assembly, isomerization reactions probably proceed at much faster rates than 
association reactions. Thus, it is expected that in the absence of PIPER the rate-limiting step 
for formation of either dimeric or tetrameric G-quadruplexes involves a bimolecular collision 
of monomeric or dimeric intermediates, respectively. Although the precise mechanism by 
which PIPER acts has yet to be established, Hurley and coworkers propose that its behaviour 
as a polynucleotide driver is due to a propensity to accelerate the association of G-rich 
oligonucleotides. Consequently, isomerization reactions become the rate-limiting events in G-
quadruplex assembly, and overall formation rates thereof are greatly enhanced (Han et al. 
1999). 
More recently, PIPER has also been shown to prevent the unwinding of G-quadruplex 
structures by yeast Sgs1 helicase (Han et al. 2000). PIPER specifically prevents the 
unwinding of G-quadruplex DNA but not duplex DNA by Sgs1. Competition experiments 
indicate that this inhibitory activity is due to the interaction of PIPER with G-quadruplex 
structures rather than the helicase itself (Han et al. 2000). Furthermore, PIPER has been 
shown to promote the induction of duplex to G-quadruplex transition in the c-myc promoter 
region (Rangan et al. 2001). As discussed in par. 1.2 and 1.5, these structurally altered DNA 
elements might serve as regulatory signals in gene expression or in telomere dynamics. In this 
paper, the authors suggest a more complex possible mechanism for the role of PIPER in 
inducing the formation of G-quadruplex structures, both from single-stranded and duplex 
DNA. In both cases PIPER self-aggregation play a fundamental role, since it is supposed to 
interact with DNA as an assembly of stacked molecules (Fig. 1.6-4). This aspect has been 
widely studied by Kerwin and coworkers (Kerwin et al. 2002, Kern et al. 2002). In a series of 
perylene diimides they observe that the ligands bind to both duplex and G-quadruplex DNA 
under low pH conditions, where the ligands are not aggregated. At higher pH, where the 
ligands are extensively aggregated, the apparent G-quadruplex DNA binding selectivity is 
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high. An explanation proposed by the authors is that the duplex DNA intercalation by these 
perylene diimides likely requires the ligand to be monomeric. In contrast, G-quadruplex DNA 
binding by perylene diimides occurs by end stacking interactions with G-tetrads. Because this 
stacking interaction requires only one free chromophore face, it is possible that G-quadruplex 
DNA binding may occur from either aggregated or monomeric ligand (Kerwin et al. 2002). 
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1.6.b. Berberine and its analogues 
 
Berberine is an alkaloid originated from Chinese herbal medicine, where it is used as an 
antibiotic (Wu et al. 1999); its anti-bacterial activity has been demonstrated against many 
species (Ghosh et al. 1985). The drug was subsequently screened for anti-cancer activity 
following evidence of anti-neoplastic properties (Zhang 1990). More recently, berberine was 
shown to be able to inhibit telomeres elongation (Naasani et al. 1999) and to bind to G-
quadruplex DNA (Ren et. al. 1999). Coralyne is a synthetic analogue of berberine (Zee-
Cheng et al. 1972) and it is well known for its ability to bind to triplex DNA (Latimer et al. 
1995). Both these compounds show a great selectivity for triplex DNA, and to minor extent to 
quadruplex DNA, with respect to duplex DNA, according to competition dialysis experiments 
(Ren et. al. 1999). 
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2. Aim of this thesis 
 
The work described in this thesis has two main targets: the synthesis of G-quadruplex 
interactive compounds and the evaluation of their efficiency in inducing and stabilizing G-
quadruplex structures and in inhibiting human telomerase. In particular, two classes of G-
quadruplex interacting compounds have been considered: (i) perylene and coronene 
derivatives and (ii) berberine analogues and derivatives. The study of their ability to induce 
different G-quadruplex DNA structures has been aimed to understand the molecular 
mechanism of their action and the molecular features that are important in determining their 
selectivity towards different G-quadruplex topologies. Another very important aspect that has 
been considered is the selectivity of these compounds towards G-quadruplex DNA with 
respect to duplex DNA. To these aims, several experimental (PAGE, FRET, absorption 
spectroscopy) and theoretical (molecular modeling) techniques have been used. Finally, 
biological assays (TRAP) have been performed to evaluate the ability of the investigated 
compounds to inhibit human telomerase.  
 41 
 
 
3. Materials and methods 
 
3.1. Synthesis  
 
3.1.a. Perylene diimides 
 
Perylene diimides (Fig. 3.1.a-1), except PIPER7, were prepared from 3,4,9,10-
perylenetetracarboxylic dianhydride (3g) and the appropriate primary amine (10% excess), in 
a refluxing mixture of N,N-dimethylacetamide (20ml) and 1,4-dioxane (20ml). The reaction 
products were precipitated adding water and separated by filtration. The resulting products 
(80-95% yield) were purified dissolving in 0.2M HCl and precipitating the respective 
hydrochlorides with acetone (75% yield). PIPER7 was prepared from PIPER2 (200mg) by 
reaction with methyl-trifluoromethanesulfonate (10 equiv) in refluxing 1,2-dichloroethane 
(10ml), with stirring for two days (Mitkin et al. 2001). The reaction product was filtered, 
washed with chloroform and dried under vacuum. Then it was dissolved in 0.1M HCl and 
passed through a strong basic anion exchange resin Dowex1 (Fig. 3.1.a-2). PIPER7 was 
precipitated as hydrochloride with acetone in 12% total yield. Compounds were dried under 
vacuum and characterized by 1H and 13C-NMR spectroscopy (CF3CO2D, 300 MHz, 25°C) 
and elemental analysis or mass spectrometry. All perylene derivatives have been 
characterized and used as hydrochlorides (Rossetti et al. 2002, Rossetti et al. 2004).  
 
PIPER (N,N’-bis[2-(1-piperidino)ethyl]-3,4,9,10-perylenetetracarboxylic diimide): 1H 
NMR δ: 1.7-1.9 (2H), 2.0-2.4 (10H), 3.23 (4H), 3.83 (4H), 4.10 (4H), 4.93 (4H), 7.41 (2H), 
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Fig. 3.1.a-1: Structures of the synthesized perylene diimides (top) and the scheme of 
their synthesis (bottom). 
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Fig. 3.1.a-2: Scheme of the preparation of PIPER7. 
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8.92 (8H); 13C NMR δ: 11.6, 13.9, 26.7, 46.2, 47.5, 112.4, 115.4, 117.4, 120.3, 124.2, 127.4, 
157.1; elemental analysis calculated (C38H38N4O4Cl2): 66.6%C, 5.5%H, 8.2%N; found: 
64.9%C, 5.9%H, 7.8%N. ESI m/z: 613 (MH+).  
PIPER2 (N,N’-bis[2-(2-pyridino)ethyl]-3,4,9,10-perylenetetracarboxylic diimide): 1H 
NMR δ: 4.00 (4H), 5.09 (4H), 8.26 (2H), 8.45 (2H), 8.86 (2H), 9.00 (2H), 9.0–9.2 (8H); 13C 
NMR δ: 26.0, 33.0, 115.0, 117.9, 119.2, 119.9, 121.9, 122.8, 126.6, 129.8, 134.5, 141.3, 
147.5, 159.1; elemental analysis calculated (base, C38H24N4O4): 76.0%C, 4.0%H, 9.3%N; 
found: 75.3%C, 4.2%H, 9.25%N. 
PIPER3 (also known as Tel08, Kerwin et al. 2002, Kern et al. 2002) (N,N’-bis[2-(1-
piperazino)ethyl]-3,4,9,10-perylenetetracarboxylic diimide): 1H NMR δ: 4.1-4.5 (16H), 
4.78 (4H), 5.13 (4H), 9.0-9.2 (8H); 13C NMR δ: 31.2, 37.8, 45.5, 52.8, 117.5, 120.4, 122.5, 
125.4, 129.3, 132.5, 162.5; elemental analysis calculated (C36H38N6O4Cl2): 56.8%C, 5.0%H, 
11.1%N; found: 54.9%C, 5.7%H, 10.4%N. 
PIPER4 (also known as Tel10, Kerwin et al. 2002, Kern et al. 2002) (N,N’-bis[2-(4-
morpholino)ethyl]-3,4,9,10-perylenetetracarboxylic diimide): 1H NMR δ: 3.66 (4H), 4.07 
(4H), 4.3-4.5 (8H), 4.57 (4H), 5.04 (4H), 8.9-9.1 (8H); 13C NMR δ: 31.5, 49.4, 53.3, 60.2, 
117.6, 120.6, 122.6, 125.5, 129.4, 132.6, 162.3; elemental analysis calculated 
(C36H34N4O6Cl2): 62.7%C, 4.9%H, 8.12%N; found: 60.8%C, 5.4%H, 7.5%N. 
PIPER5 (also known as Tel01, Kerwin et al. 2002, Kern et al. 2002) (N,N’-bis[3-(4-
morpholino)propyl]-3,4,9,10-perylenetetracarboxylic diimide): 1H NMR δ: 2.73 (4H), 
3.62 (4H), 3.77 (4H), 4.02 (4H), 4.38 (4H), 4.59 (4H), 4.72 (4H), 8.9-9.1 (8H); 13C NMR δ: 
18.5, 33.9, 48.6, 52.0, 60.1, 117.7, 120.3, 122.2, 125.2, 129.0, 132.1, 161.8; elemental 
analysis calculated (C38H38N4O6Cl2): 63.6%C, 5.3%H, 7.8%N; found: 61.8%C, 5.8%H, 
7.6%N.  
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PIPER6 (N,N’-bis[2-(2-(1-methyl)pyrrolidino)ethyl]-3,4,9,10-perylenetetracarboxylic 
diimide): 1H NMR δ: 2.2-2.4 (8H), 2.83 (4H), 3.29 (6H), 3.47 (2H), 3.82 (2H), 4.13 (2H), 
4.66 (4H), 7.79 (2H), 9.00 (8H); 13C NMR δ: 17.4, 25.2, 25.4, 33.9, 36.6, 53.4, 65.2, 117.8, 
120.4, 122.4, 125.3, 129.1, 132.2, 161.7; elemental analysis calculated (C38H38N4O4Cl2): 
66.7%C, 5.5%H, 8.2%N; found: 63.8%C, 6.1%H, 8.2%N. 
PIPER7 (N,N’-bis[2-(2-(1-methyl)pyridino)ethyl]-3,4,9,10-perylenetetracarboxylic 
diimide): 1H NMR δ: 4.23 (t, J = 7.3, 4H), 5.11 (s,6H), 5.28 (t, J = 7.3, 4H), 8.40 (t, J = 7.4, 
2H), 8.57 (d, J = 7.4, 2H), 8.91 (t, J = 7.4, 2H), 9.21 (d, J = 7.4, 2H), 9.31 (d, J = 8.2, 4H), 
9.37 (d, J = 8.2, 4H); 13C NMR δ: 27.3, 34.5, 41.9, 117.8, 120.6, 122.6, 125.5, 125.8, 129.3, 
132.6, 142.2, 142.5, 151.4, 161.8. ESI m/z: 629 [(M-1)+], 315 [(M/2)2+]. 
 
The commercially available DAPER (Liu et al. 1996) was purchased by Sigma-Aldrich and 
used without further purification. 
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3.1.b. New perylene derivatives 
 
In order to achieve more water-soluble perylene diimides, a synthetic strategy already applied 
in the synthesis of lipophilic perylene derivatives used as liquid crystalline dyes was applied 
(Fig. 3.1.b-1, Franceschin et al. 2004). In particular, the same strategy described by Mullen 
and coworkers (bromination of the bay-area of 3,4,9,10-perylenetetracarboxylic dianhydride 
1) was considered (Rohr et al. 1998, Rohr et al. 2001), combined with the preparation of 
perylene diimides with hydrophilic side chains (Rossetti et al. 2002), to obtain the brominated 
perylene diimide 3 PIPER-Br (Scheme 1), onto which two other hydrophilic substituents 
could be inserted. When bromine atoms on the perylene bay-area are substituted by piperidine 
or morpholine rings, new highly water-soluble perylene derivatives (4) are obtained (Scheme 
2A).  
The twofold bromination of the commercially available perylene-3,4:9,10-tetracarboxylic 
dianhydride (1) was easily carried out with elemental bromine in 96% sulphuric acid to give a 
mixture of the two isomers 2a and 2b in 98% yield (Scheme 1). The dianhydride 1 (9g) was 
initially dissolved in 96% sulphuric acid (150ml) and stirred for 4h at room temperature. 
Elemental iodine (200mg) was subsequently added and the mixture was heated. When a 
temperature of 80°C was reached, elemental bromine (3ml) was added drop wise, achieving a 
final excess of 20%. The reaction mixture was stirred at 80°C overnight. After cooling, it was 
added drop wise to ice and then filtered and washed with a 5% sodium metabisulfite solution 
to provide a red solid, that was dried and characterized. The two isomers (2a and 2b) could 
not be separated and the isomeric mixture was used in the following step, in which the 
commercially available 1-(2-aminoethyl)piperidine was added to give a mixture of the two 
isomers 3a and 3b (Scheme 1). 6g of  2, obtained in the previous reaction, and 3.6ml of 1-(2-
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Scheme 1 
Scheme 2A 
Fig. 3.1.b-1: Scheme for the synthesis of the new perylene derivatives 
(Franceschin et al. 2004). 
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aminoethyl)piperidine were stirred in a refluxing mixture of N,N-dimethylacetamide (DMA, 
60ml) and 1,4-dioxane (60ml) for 6h. After cooling, water was added and a red solid was 
separated by filtration (71% yield). This mixture of isomers (3) was used in the following 
steps (Schemes 2A and 2B). 
When reacting 3 with piperidine (X=CH2 in Scheme 2A) two isomers [4a(I) and 4b(I)] were 
separated and characterized. 250mg of 3 were stirred under argon in a refluxing mixture of 
tetrahydrofuran (THF, 20ml) and piperidine (20ml) for 36h. After cooling, water was added 
and the crude product was extracted with ethyl acetate. The organic layer was extracted with 
water until the aqueous layer was neutral. The two isomers [4a(I) (30%) and 4b(I) (5%), PIP-
PIPER (1,7) and (1,6) respectively] were isolated by column chromatography on silica gel 
(CHCl3). A standard commercial silica gel had been previously washed with 1N HCl, 
followed by water until the chlorine test was negative, activated at 120°C for 48h, and finally 
equilibrated with 10% water (Bianco et al. 2004). In order to obtain the water soluble 
hydrochlorides, these compounds were dissolved in 0.2M HCl and, after filtration, the 
solution was concentrated under vacuum, adding repeatedly an equal volume of chloroform 
until water had been eliminated completely. When repeating the same experimental 
conditions using morpholine (X=O in Scheme 2A) only the isomer 4b(II) [MORPHO-
PIPER(1,6)] has been isolated from the chromatographic column (5% yield). With reaction 
times under 12h, monosubstituted derivatives can be obtained. In particular, it was possible to 
purify and characterize the compound 10 (30% yield, Fig. 3.1.b-1). 
 
1,7-dibromoperylene-3,4:9,10-tetracarboxylic dianhydride (2a) 1H NMR (200 MHz, 
D2SO4): δ 10.42 (d, J = 8Hz, 2H, aromatic H), 9.75 (s, 2H, aromatic H), 9.53 (d, J = 8Hz, 2H, 
aromatic H). The signals of the minor (1,6) isomer (2b) are mainly superimposed with those 
reported for 2a, a part from the doublet centred at 10.34 ppm, that is sufficiently separated 
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from the other signals to be integrated, giving a ratio between 2a and 2b of 6:1. C24H6O6Br2: 
calcd. C 52.4, H 1.1%; found C 51.6, H 1.1%. 
N,N’-bis[2-(1-piperidino)-ethyl]-1,7-dibromoperylene-3,4:9,10-tetracarboxylic diimide 
(PIPER-Br, 3a) 1H NMR (300 MHz, CDCl3): δ 9.44 (d, J = 8Hz, 2H, aromatic H), 8.89 (s, 
2H, aromatic H), 8.67 (d, J = 8Hz, 2H, aromatic H), 4.41 (t, J = 7Hz, 4H, Nimidic-CH), 2.8-2.6 
(broad, 12H, Npiperidine-CH), 1.8-1.4 (broad, 12H, CHpiperidine); 13C NMR APT (200 MHz, 
CDCl3): δ 162.14 (C=O), 161.64 (C=O), 137.31 (CH ar.), 132.17 (C ar), 132.02 (C ar.), 
129.29 (CH ar.), 128.50 (C ar.), 127.78 (CH ar.), 126.28 (C ar.), 122.55 (C ar.), 122.12 (C 
ar.), 120.18 (C ar.), 55.74, 54.24, 37.41, 25.48, 23.81. MS (ESI) m/z: 771.10 [(M+1)+] (calcd. 
for C38H34N4O4Br2 M = 770.09). In this case, all 1H NMR signals of the two isomers are 
superimposed and it is not possible to obtain the isomeric ratio. 
N,N’-bis[2-(1-piperidino)-ethyl]-1,7-bis(1-piperidinyl)perylene-3,4:9,10-tetracarboxylic 
diimide [PIP-PIPER(1,7), 4a(I)]: 1H NMR (200 MHz, CDCl3): δ 9.46 (d, J = 8Hz, 2H, 
aromatic H), 8.33 (s, 2H, aromatic H), 8.30 (d, J = 8Hz, 2H, aromatic H), 4.32 (t, J = 7Hz, 4H, 
Nimidic-CH), 3.38 (m, 4H, Car-Npiperidine-CH), 2.81 (m, 4H, Car-Npiperidine-CH), 2.7-2.4 (broad, 
12H, Npiperidine-CH), 1.8-1.5 (broad, 24H, CHpiperidine); 13C NMR APT (200 MHz, CDCl3): δ 
163.05 (C=O), 162.91 (C=O), 150.20 (C ar.), 134.90 (C ar.), 129.36 (C ar.), 127.50 (CH ar.), 
123.70 (C ar.), 123.17 (CH ar.), 122.64 (CH ar.), 122.34 (C ar.), 121.85 (C ar.), 120.30 (C 
ar.), 55.87, 54.21, 52.27, 37.15, 25.50, 25.21, 23.88, 23.27. MS (ESI) m/z: 779.41 [(M+1)+] 
(calcd. for C48H54N6O4 M = 778.42). 
N,N’-bis[2-(1-piperidino)-ethyl]-1,6-bis(1-piperidinyl)perylene-3,4:9,10-tetracarboxylic 
diimide [PIP-PIPER(1,6), 4b(I)]: 1H NMR (200 MHz, CDCl3): δ 9.63 (d, J = 8Hz, 2H, 
aromatic H), 8.53 (d, J = 8Hz, 2H, aromatic H), 8.31 (s, 2H, aromatic H), 4.30 (m, 4H, Nimidic-
CH), 3.29 (m, 4H, Car-Npiperidine-CH), 2.79 (m, 4H, Car-Npiperidine-CH), 2.7-2.4 (broad, 12H, 
Npiperidine-CH), 1.9-1.5 (broad, 24H, CHpiperidine); 13C NMR (200 MHz, CDCl3): δ 163.23 
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(C=O), 163.10, (C=O), 152.76 (ar.), 135.60 (ar.), 131.24 (ar.),  130.21 (ar.), 128.34 (ar.), 
127.51 (ar.), 123.26 (ar.), 122.69 (ar.), 122.61 (ar.), 121.85 (ar.), 120.20 (ar.), 119.68 (ar.), 
55.91, 54.22, 52.63, 37.24, 37.06, 25.51, 25.28, 23.84, 23.27. MS (ESI) m/z: 779.43 [(M+1)+] 
(calcd. for C48H54N6O4 M = 778.42). 
N,N’-bis[2-(1-piperidino)-ethyl]-1,6-bis(4-morpholinyl)perylene-3,4:9,10-tetracarboxylic 
diimide [MORPHO-PIPER(1,6), 4b(II)]: 1H NMR (200 MHz, CDCl3): δ 9.80 (d, J = 8Hz, 
2H, aromatic H), 8.55 (d, J = 8Hz, 2H, aromatic H), 8.32 (s, 2H, aromatic H), 4.31 (m, 4H, 
Nimidic-CH), 3.87 (m, 8H, CHmorpholine), 3.19 (m, 4H, CHmorpholine), 3.03 (m, 4H, CHmorpholine), 
2.6-2.4 (broad, 12H, Npiperidine-CH), 1.6-1.3 (broad, 12H, CHpiperidine); 13C NMR (200 MHz, 
CDCl3): δ 162.45 (C=O), 162.41 (C=O), 151.07 (ar.), 134.44 (ar.), 130.81 (ar.), 129.68 (ar.), 
127.84 (ar.), 127.29 (ar.), 123.35 (ar.), 122.70 (ar.), 122.57 (ar.), 120.98 (ar.), 120.54 (ar.), 
119.93 (ar.), 65.52, 55.29, 53.70, 50.79, 36.80, 36.57, 24.92, 23.31. MS (ESI) m/z: 783.39 
[(M+1)+] (calcd for C46H50N6O6 M = 782.38). 
N,N’-bis[2-(1-piperidino)-ethyl]-1-bromo-7-(4-morpholinyl)perylene-3,4:9,10-
tetracarboxylic diimide (10): 1H NMR (200 MHz, CDCl3): δ 9.61 (d, J = 8Hz, 1H, aromatic 
H), 9.30 (d, J = 8Hz, 1H, aromatic H), 8.73 (s, 1H, aromatic H), 8.51 (d, J = 8Hz, 1H, 
aromatic H), 8.44 (d, J = 8Hz, 1H, aromatic H), 8.39 (s, 1H, aromatic H), 4.31 (m, 4H, Nimidic-
CH), 3.86  (m, 4H, CHmorpholine), 3.28 (m, 2H, CHmorpholine), 3.10 (m, 2H, CHmorpholine), 2.7-2.4 
(broad, 12H, Npiperidine-CH), 1.6-1.3 (broad, 12 H, CHpiperidine). MS (ESI) m/z: 776.31 [(M+1)+] 
(calcd for C42H42N5O5Br M = 775.24). 
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3.1.c. CORON: a new hydrosoluble coronene derivative 
 
When bromine atoms on the perylene bay-area of PIPER-Br are substituted by the piperidine 
containing 1-alkyne 7 a two steps cyclization can occur, leading to the new hydrophilic 
coronene derivative 6 CORON (Fig. 3.1.c-1, Franceschin et al. 2004). 3 was reacted with the 
previously prepared 7 to give the intermediate 5, using the conditions previously described by 
Sonogashira et al. (1975); 5 was found to be already partially closed to coronene and provided 
6 in the following cyclization step (Scheme 2B). In this case, the minor isomer due to the 
initial presence of 1,6-dibromoperylene diimide 3b cannot be separated from the major 
isomer, which is the only one reported in Scheme 2B. 7 was prepared from the commercially 
available 3-butyn-1-ol by a mesylate conversion: 3-butyn-1-ol was converted into its mesylate 
(Crossland et al. 1970), 1g of which, without purification, was stirred with piperidine 
(1.35ml) in refluxing absolute ethanol overnight under nitrogen. After cooling, solvent was 
evaporated under vacuum, then dichloromethane was added and the organic layer was 
repeatedly washed with saturated NaCl solution. Finally the organic layer was dried under 
vacuum to give 390mg of liquid 7 (42% yield). 2g of 3 were dissolved in anhydrous THF 
(80ml) and triethylamine (80ml), then CuI (50mg) and Pd(PPh3)4 (240mg) were added. After 
adding 1.45g of 7, argon was bubbled into the reaction mixture that was then refluxed with 
stirring under argon for 24h. After cooling, 150ml of diluted HCl (HCl:H2O 1:3) were added 
and the product was extracted with dichloromethane, after neutralization with NaOH 2M. The 
organic layer was extracted with water until the aqueous layer was neutral. The crude product 
was purified by column chromatography on a silica gel (CHCl3:MeOH 100:0, 98:2, 95:5, 
90:10) to give 510 mg (22% yield) of intermediate 5, together with a small amount of 6. 
Separation and better characterization were not possible at this stage, and the entire mixture 
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Scheme 1 
Scheme 2B 
Fig. 3.1.c-1: Scheme for the synthesis of the coronene derivative (6). In Scheme 2B only 
the major isomers are reported (Franceschin et al. 2004). 
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was used in the following cyclization step. The mixture was poured into 50ml of toluene and 
0.17ml of 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) were added. The reaction mixture was 
refluxed with stirring under argon for 20h. After cooling, water was added and the crude 
product was extracted with dichloromethane. The organic layer was extracted with water until 
the aqueous layer was neutral. The crude product was purified by column chromatography on 
a silica gel (CHCl3:MeOH 100:0, 98:2, 95:5, 90:10, 80:20) to give 160 mg (31% yield) of 
compound 6. It was then purified dissolving in 0.2M HCl and precipitating the respective 
hydrochloride with acetone (64% yield). 
 
1-(3-butynyl)-piperidine (7): 1H NMR (200 MHz, CDCl3): δ 2.49 (m, 2H, ≡C-CH), 2.4-2.2 
(broad, 6H, N-CH), 1.90 (t, J = 3 Hz, 1H, C≡C-H), 1.53 (m, 4H, CHpiperidine), 1.37 (m, 2H, 
CHpiperidine); 13C NMR (200 MHz, CDCl3): δ 82.50 (≡C), 68.30 (≡CH), 57.29, 53.64, 25.36, 
23.74, 16.10. 
N,N’-bis[2-(1-piperidino)-ethyl]-5,11-bis[2-(1-piperidino)-ethyl]-coronene-2,3:8,9- 
tetracarboxylic diimide (CORON, 6): 1H NMR (300 MHz, CDCl3): δ 9.22 (s, 2H, aromatic 
H), 9.02 (s, 2H, aromatic H), 8.25 (s, 2H, aromatic H), 4.61 (t, J = 7Hz, 4H, Nimidic-CH), 3.66 
(m, 4H, Car-CH), 3.1-2.5 (broad, 24H,  Npiperidine-CH), 1.9-1.4 (broad, 24H, CHpiperidine). 13C 
NMR (300 MHz, CDCl3): δ 163.66 (C=O), 163.50 (C=O), 138.63 (ar.), 130.77 (ar.), 128.70 
(ar.), 127.98 (ar.), 127.72 (ar.), 127.40 (ar.), 124.75 (ar.), 121.26 (ar.), 120.80 (ar.), 120.35 
(ar.), 120.12 (ar.), 118.62 (ar.), 60.23, 56.55, 54.92, 54.81, 38.20, 30.86, 26.24, 24.57. 
Aromatic 1H NMR singlets due to the minor (5,10) isomer can be detected at 9.28 and 8.92 
ppm. Integration of the signals shows that the ratio of the two isomers is about 5:1. It is worth 
noting that the strong ring-current effect of the coronene system leads to unusually high 
deschielding of about 1-2 ppm, in comparison with a benzenic system, both of the aromatic 
and benzilic-like protons. 1H NMR (300 MHz, CF3COOD, hydrochloride): δ 10.74 (s, 2H, 
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aromatic H), 10.51 (s, 2H, aromatic H), 9.64 (s, 2H, aromatic H), 5.38 (m, 2H, Nimidic-CH), 
4.88 (m, 2H, Nimidic-CH), 4.5-4.1 (broad, 16H, Npiperidine-CH + Car-CH), 3.7-3.4 (broad, 12H, 
Npiperidine-CH), 2.6-1.9 (broad, 24H, CHpiperidine); 13C NMR (300 MHz, CF3COOD, 
hydrochloride): δ 163.51 (C=O), 163.07 (C=O), 131.35 (ar.), 128.94 (ar.), 127.27 (ar.), 126.84 
(ar.), 125.55 (ar.), 123.87 (ar.), 121.48 (ar.), 120.39 (ar.), 119.42 (ar.), 118.03 (ar.), 116.95 
(ar.), 116.71 (ar.), 54.53, 52.73, 51.47, 51.21, 32.35, 24.37, 19.35, 19.22, 17.14. MS (ESI) 
m/z: 883.49 [(M+1)+] (calcd for C56H62N6O4 M = 882.48). 
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3.1.d. Berberine analogues and derivatives 
 
Since the natural compound berberine shows a very interesting N+-containing aromatic 
moiety and was previously shown to be able to inhibit telomeres elongation (Naasani et al. 
1999) and to bind to G-quadruplex DNA (Ren et al. 1999, par. 1.6.b), it has been interesting 
to add a side chain analogue to that of PIPER on this molecular moiety, which shows G-
quadruplex induction and stabilization, even without any side chain (par. 4.3 and 4.6). The 
synthetic strategy, reported in Fig. 3.1.d-1, uses a previously described acetonyl-berberine 
intermediate A (Kim et al. 1999), that can be transformed in the second intermediate B. 
Iodine on B can be easily replaced by piperidine to obtain the desired side chain of C. Using 
different secondary amines, a series of different side chains can be easily obtained, similarly 
to the series of perylene diimides.  
3g of berberine chloride were dissolved in 18ml of water and 4.5ml of NaOH 50% solution 
were added. While stirring, 3.0ml of acetone were added drop wise. After stirring for 30 
minutes at room temperature, the reaction mixture was filtered and washed with 80% 
methanol to give 2.65g of A (83.5% yield). It was dissolved in 75ml of CH3CN and 7.4ml of 
1,3-diiodopropane were added. The reaction mixture was stirred at 80°C for 6h. After cooling, 
it was filtered and washed repeatedly with acetonitrile. The crude product was purified by 
column chromatography on a silica gel (CHCl3:MeOH 9:1 and then 8:2) to give 370mg (8.7% 
yield) of B. They were reacted for 4 hours with 0.86ml of piperidine in 36ml of refluxing 
ethanol. After cooling, the reaction mixture was dried under vacuum and the crude product 
was purified by column chromatography on a silica gel equilibrated with 10% of water 
(CHCl3) to give 265mg (77% yield) of C. In order to obtain the respective hydrochloride, it 
was then dissolved in 0.1M HCl and passed through a strong basic anion exchange resin 
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Dowex1. The acid solution was concentrated under vacuum, adding repeatedly an equal 
volume of chloroform, until a powder was obtained, that was then dried under vacuum. 
 
8-acetonyldihydroberberine (A): 1H NMR (300 MHz, CDCl3): δ 7.13 (s, 1H, aromatic H), 
6.77 (d, J = 8 Hz, 1H, aromatic H), 6.75 (d, J = 8 Hz, 1H, aromatic H), 6.57 (s, 1H, aromatic 
H), 5.94 (m, 2H, O-CH2-O), 5.89 (s, 1H, aromatic H), 5.32 (dd, X part of ABX system, 1H, 
JAX=7Hz, JBX=4Hz, CH-N), 3.89 (s, 3H, CH3-O), 3.84 (s, 3H, CH3-O), 3.34 (m, 2H, CH2-N), 
3.07 (dd, A part of ABX system, 1H, JAX=7Hz, JAB=15Hz, N-CH-CO), 2.79 (m, 2H, CH2-Ar), 
2.41 (dd, B part of ABX system, 1H, JBX=4Hz, JAB=15Hz, N-CH-CO), 2.05 (s, 3H, CH3-CO). 
13-(3-iodopropyl)berberine iodide (B): 1H NMR (300 MHz, CDCl3): δ 10.26 (s, 1H, 
aromatic H), 8.00 (d, J = 9 Hz, 1H, aromatic H), 7.89 (d, J = 9 Hz, 1H, aromatic H), 7.09 (s, 
1H, aromatic H), 6.89 (s, 1H, aromatic H), 6.10 (s, 2H, O-CH2-O), 5.08 (bs, 2H, CH2-N+), 
4.37 (s, 3H, CH3-O), 4.07 (s, 3H, CH3-O), 3.51 (t, J = 8Hz, 2H, CH2-Ar), 3.32 (t, J = 6Hz, 2H, 
CH2-Ar), 3.23 (t, J = 5Hz, 2H, CH2-I), 2.30 (m, 2H, CH2(propyl)).  
13-[3-(1-piperidino)propyl]berberine iodide (C): 1H NMR (300 MHz, CDCl3): δ 9.69 (s, 
1H, aromatic H), 8.20 (d, J = 9 Hz, 1H, aromatic H), 7.93 (d, J = 9 Hz, 1H, aromatic H), 7.10 
(s, 1H, aromatic H), 6.88 (s, 1H, aromatic H), 6.15 (s, 2H, O-CH2-O), 4.78 (bs, 2H, CH2-N+), 
4.31 (s, 3H, CH3-O), 4.09 (s, 3H, CH3-O), 3.63 (t, J = 7Hz, 2H, CH2-Ar), 3.43 (m, 2H, CH2-
Ar), 3.11 (bs, 4H, CH2-Npiperidine), 2.98 (t, J = 8Hz, 2H, CH2-Npiperidine), 2.35 (bs, 2H, 
CH2(propyl)), 1.87 (bs, 4H, CH2-βpiperidine), 1.60 (bs, 2H, CH2-γpiperidine). 13C NMR (300 MHz, 
CDCl3): δ 150.55 (ar.), 150.31 (ar.), 147.68 (ar.), 145.22 (ar.), 144.80 (ar.), 136.51 (ar.), 
133.02 (ar.), 132.68 (ar.), 125.62 (ar.), 122.16 (ar.), 121.01 (ar.), 119.86 (ar.), 109.74 (ar.), 
108.36 (ar.), 102.32 (ar.), 68.16, 62.43, 57.84, 56.88, 55.65, 52.77, 28.25, 26.88, 25.27, 23.13, 
21.75. MS (ESI) m/z: 461.0 [M+] (calcd for C28H33N2O4 M =461.2). 
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13-[3-(1-piperidino)propyl]berberine hydrochloride (piperidin-berberine): 1H NMR (300 
MHz, D2O, HDO suppressed): δ 9.57 (s, 1H, aromatic H), 8.03 (d, J = 9 Hz, 1H, aromatic H), 
7.97 (d, J = 9 Hz, 1H, aromatic H), 7.13 (s, 1H, aromatic H), 6.94 (s, 1H, aromatic H), 5.99 (s, 
2H, O-CH2-O), 4.75 (m, 2H, CH2-N+), 3.98 (s, 6H, CH3-O), 3.42 (t, J = 7Hz, 2H, CH2-Ar), 
3.25 (m, 2H, CH2-Ar), 2.98 (bs, 4H, CH2-Npiperidine), 2.72 (t, J = 9Hz, 2H, CH2-Npiperidine), 1.98 
(m, 2H, CH2(propyl)), 1.74 (m, 4H, CH2-βpiperidine), 1.55 (m, 2H, CH2-γpiperidine). Elemental 
analysis calculated for C28H34N2O4Cl2•CHCl3: 53.3%C, 5.4%H, 4.3%N; found: 54.1%C, 
6.1%H, 4.4%N.  
 
The berberine analogue coralyne has been purchased from Sigma-Aldrich and used without 
further purification (par. 4.1). 
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3.2. Instruments for the characterization of the synthesized 
compounds 
 
Nuclear Magnetic Resonance (NMR): 1H and 13C-NMR spectra were performed on 
Varian Gemini 200 and Varian Mercury 300 MHz instruments.  
 
Elemental analysis: The elemental analysis of the synthesized compounds was 
performed at the “Servizio di Microanalisi” of the Department of Chemistry using an 
EA1110 CHNS-O (CE) instrument. 
 
UV/Vis absorption spectra: New perylene and coronene derivatives spectra were performed at 
300K using a JASCO V-530 spectrophotometer. As for perylene diimides without substitution 
on the bay-area, 1mM DMSO stocks were diluted to the final desired concentration in the 
selected buffer. In this last case a Varian “Cary 50” spectrophotometer was used. 
 
Mass spectrometry: ESI spectra were performed on high resolution Micromass  MS/MS Q-
TOF MICRO instrument. 
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3.3. Biophysical and biological assays 
 
3.3.a. Gel shift assays by PAGE (PolyAcrylamide Gel Electrophoresis) 
 
The ability of the studied compounds to induce the formation of inter- and intramolecular G-
quadruplex structures was investigated by PAGE (PolyAcrylamide Gel Electrophoresis). In 
fact, G-quadruplex DNA structures involving a different number of oligonucleotides and with 
different shapes, have a different electrophoretic mobility, which depends on the molecular 
weight and conformation of macromolecules (Cantor et al. 1980, p. 676). If a macromolecule 
has a net charge q, then application of an electric field E will result in an applied force F=qE. 
This force will cause acceleration of the particle in a fluid until a steady-state velocity v is 
reached. At this velocity, frictional forces are equal and opposite to the applied force, so 
v = qE/f 
If the electrical field originates from parallel plates or the equivalent, the molecule travels in a 
straight line; the electrophoretic mobility u can be defined as the velocity per unit field: 
u = v/E = q/f 
This means that the electrophoretic mobility does not depend on the applied electrical field, 
but only on the macromolecule charge (q) and its translational frictional coefficient (f), that in 
turn depends on the shape and dimensions of the macromolecule. This relationship allows to 
use electrophoresis to obtain information about relative charge (for molecules of the same size 
and shape) or about relative size (for molecules of the same charge).  
In aqueous solution, the presence of counterions and diffusion phenomena make difficult to 
elaborate a quantitative theory that allows to obtain structural data. Despite all these 
complications, electrophoresis is a powerful and practical tool in the analysis and separation 
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of proteins and nucleic acids. In fact, these problems can be minimized in zonal 
electrophoresis, using a solid support permeated with buffer. In particular, polyacrylamide 
and agarose gels retard the motion of certain molecules relative to one another, so that 
macromolecules can be discriminated by shape and molecular weight. The use of a solid 
support makes a quantitative analysis of mobility nearly impossible, but useful information 
can be obtained if suitable standards and references are provided. 
 
Oligonucleotides: The DNA oligomers 2HTR (5’-
AATCCGTCGAGCAGAGTTAGGGTTAGGGTTAG-3’) and TSG4 (5’-
GGGATTGGGATTGGGATTGGGATT-3’) used in the experiments reported in this thesis 
were purchased from MWG. They were labelled at the 5’ end by reaction of T4 
polynucleotide kinase (2.5U/µg of DNA) for 30 minutes at 37°C in 50µL of buffer containing 
50mM Tris-HCl pH 7.5, 10mM MgCl2, 10mM 2-mercaptoethanol and 30µCi of [γ-32P] ATP. 
The reaction was quenched heating the mixture at 65°C for 10 minutes. The reaction mixture 
was then purified through phenol/chloroform and chloroform extractions. After precipitation 
with ammonium acetate and ethanol and washing with 80% ethanol, the DNA was dried and 
then dissolved in the desired amount of water. The radioactivity was quantified by Beckman 
LS 5000 TD Scintillation System.  
 
Drugs stocks preparation: Drugs samples were prepared dissolving the desired amount of drug 
in DMSO, so that to obtain 1mM stocks; further dilutions were carried out in the buffer used 
for each experiment.  
 
Gel shift assays: Oligonucleotides (8 or 12µM) were heated at 95°C for 10 minutes and 
quickly cooled in ice to disrupt any possible preformed structure. Then they were incubated 
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for 2h at 30 °C in the presence of different drugs concentrations, in MES-KCl buffer (10mM 
MES*, pH 6.5, 50mM KCl) or TRAP-derived buffers (par. 3.3.d). In particular, TRAP buffer 
(20mM Tris*-HCl (pH 7.5), 68mM KCl, 15mM MgCl2, 10mM EDTA, 0.5% Tween20) was 
used for 2HTR, while in the case of TSG4 a lower KCl concentration was used ([KCl]=5 
mM), because at higher potassium concentrations the G-quadruplex monomeric structure is 
formed also in the absence of drugs. Complexes and structures formed after incubation were 
studied by native PAGE (15% polyacrylamide gel, TBE* 0.5X, KCl 20mM, run overnight at 
4°C) (Rossetti et al. 2002, Rossetti et al. 2004, Han et al. 1999). 
 
* MES = 2-[N-morpholino]ethanesulfonic acid, Tris = Tris(hydroxymethyl)aminomethane [2-
amino-2-(hydroxymethyl)-1,3-propanediol], TBE (1X) = Tris 90 mM, boric acid 90 mM, 
EDTA 2.5 mM 
 
DMS footprinting: To verify the attribution of electrophoretic bands to G-quadruplex 
structures, dimethylsulfate (DMS) methylation protection experiments were performed. The 
N7 of guanine is directly involved in the Hoogsteen hydrogen bond of G–G base pair, so the 
formation of G-quadruplex structures should protect guanine residues from methylation by 
DMS, while guanines not involved in quadruplex structures remain susceptible (Rossetti et al. 
2002, Fig. 3.3.a-1). Oligonucleotides (free or after incubation with the drugs) were treated 
with DMS at a final concentration of 1% (v/v), for 10 minutes at room temperature. 
Immediately thereafter, the products were gel-purified by native 16% PAGE: the bands 
corresponding to single stranded and G-quadruplex DNA were separated and successively 
treated with piperidine to induce strand cleavages at methylated bases. Finally, the reaction 
products were loaded on a denaturing gel 20% polyacrylamide gel (Negri et al. 1996). In Fig. 
3.3.a-2 the results obtained for PIPER and PIPER3, that induce tetrameric and dimeric G-
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Fig. 3.3.a-1: Comparison (left) between 
Hoogsteen H-bonds of two 
guanines involved in a G-
quartet structure (a) and 
classical Watson-Crick GC base 
paring (b). The nitrogen atom 
labelled with * is the guanine 
N7 atom involved in the 
Hoogsteen paring, while it is 
free in the GC paring (Kipling 
1995). In the last case, as well 
as in single stranded DNA, it 
can be methylated by DMS 
(above). The intermediate (2) is 
easily hydrolysed in basic 
environment, and the so formed 
(3) reacts with piperidine 
leading to the cleavage of the 
oligonucleotide (4 and 5). 
Guanines protected by 
Hoogsteen H-bonds are not 
susceptible to this treatment.  
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Fig. 3.3.a-2: Dimethyl sulfate (DMS) 
footprinting. (a) 2HTR (free (1 and 6) 
and incubated with PIPER (2-3) and 
PIPER3 (4-5) at 20 and 50 µM 
respectively) was treated as described 
in the text; the products (tetramer, 
dimer and free oligomer) were gel-
purified by native PAGE (b): after 
reaction with piperidine to induce 
strand cleavages, the reaction products 
were loaded on the denaturing 
polyacrylamide gel reported in (a). 
A+G: Maxam and Gilbert reaction for 
purins. (c) Densitometric profiles of 
the corresponding lanes. 
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quadruplex structures on 2HTR respectively, are reported. The free oligomer 2HTR (lanes 1 
and 6) was uniformly methylated by DMS at every guanine residue. On the contrary, in the 
case of the tetrameric (lanes 2 and 3) and dimeric (lanes 4 and 5) G-quadruplex complexes, 
induced, respectively, by PIPER and PIPER3, the guanines that were within the two human 
telomeric repeats resulted protected, while the guanine residues in the tail remained always 
sensitive. All these data confirm that the bands with different electrophoretic mobility with 
respect to single stranded DNA induced by PIPER and PIPER3 correspond to G-quadruplex 
structures stabilized by the association of four guanines in a cyclic Hoogsteen hydrogen-
bonding arrangement. Analogues experiments have been performed with the other drugs and 
the TSG4 oligomer, to confirm G-quadruplex formation. 
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3.3.b. Absorption and circular dichroism spectroscopy 
 
UV/Vis absorption spectra of perylene diimides in the presence of different concentrations of 
duplex and quadruplex DNA were performed using a spectrophotometer Varian “Cary 50”. 
Circular dichroism spectra were performed on Jasco “J-7000”.  
Absorption spectra were registered between 350 and 650 nm in polystyrene cuvettes, in order 
to minimize adsorption phenomena of perylene derivatives, which can occur using glass 
cuvettes. 1mM drug stocks were diluted in MES buffer (10mM, pH 6.5) to 10µM. 
Oligonucleotides representing models for G-quadruplex structures were purchased from 
MWG and dissolved in buffer containing MES 10mM pH 6.5, KCl 100mM, EDTA 0.01mM. 
Then, they were annealed heating the sample at 95°C for 2 minutes and cooling slowly to 
room temperature. Circular dichroism spectra were registered and compared to those reported 
in the literature, to be sure of the correct G-quadruplex folding. In particular, in Fig. 3.3.b-1 
circular dichroism spectra of (T4G4)2 before and after annealing are reported. As duplex 
model, calf thymus DNA was considered. Since its average length is 13kb, it was treated with 
ultrasound (Soniprep 150 sonicator) for 8 minutes to obtain an average length of 500bp 
(according to gel electrophoresis analysis with Mass Ruler DNA ladder mix - low range). The 
concentrations of the various DNA were determined by measurement of absorbance at 
260nm. Initial DNA concentration was 800µM; adding increasing volumes of 10µM drug 
stock the DNA/drug ratio was decreased until a final DNA concentration of 20µM, while 
taking constant drug concentration. 
Preliminary experiments of circular dichroism were performed, using solutions prepared 
separately at the desired drug/DNA ratio.  
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Fig. 3.3.b-1: Circular dichroism spectra of  (T4G4)2 in MES/KCl buffer (MES 10 mM pH 
6.5, KCl 100 mM) before () and after (- - - - -) the annealing at 95 °C. 
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3.3.c. Fluorescence Resonance Energy Transfer (FRET) assays 
 
Fluorescence resonance energy transfer (FRET) is a distance-dependent interaction between 
the electronic excited states of two dye molecules in which excitation is transferred from a 
donor molecule to an acceptor molecule without emission of a photon. Primary conditions for 
FRET are: 1) donor and acceptor molecules must be in close proximity (typically 10–100 Å); 
2) the absorption spectrum of the acceptor must overlap the fluorescence emission spectrum 
of the donor (Fig. 3.3.c-1(a)); 3) donor and acceptor transition dipole orientations must be 
approximately parallel (Cantor et al. 1980, p. 448).   
The efficiency of FRET is dependent on the inverse sixth power of the intermolecular 
separation (Fig. 3.3.c-1(b)), making it useful over distances comparable with the dimensions 
of biological macromolecules. In most applications, the donor and acceptor dyes are different, 
in which case FRET can be detected by the appearance of sensitized fluorescence of the 
acceptor or by quenching of donor fluorescence. 
FRET can be used to probe the secondary structure of oligodeoxynucleotides mimicking 
repeats of the G-rich strand of vertebrate telomeres, provided a fluorescein (donor) molecule 
and a tetramethylrhodamine (acceptor) derivative are attached to the 5’- and 3’-ends of the 
oligonucleotide, respectively (Koeppel et al. 2001). In the unfolded form, little transfer is 
expected, as the average distance of the two chromophores is larger than the Förster critical 
distance (calculated to be ≈5.0 nm, Fig. 3.3.c-1). Intramolecular folding into a G-quadruplex 
should bring the two chromophores in close enough proximity to observe energy transfer. 
Therefore, FRET should be a convenient method to monitor the 3’- to 5’-end distance 
(Koeppel et al. 2001). 
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Fig. 3.3.c-1: (a) Schematic representation of the superimposing of the absorption 
spectrum of the acceptor and the fluorescence emission spectrum of the 
donor. (b) Relationship between the efficiency of the fluorescence 
resonance energy transfer and the distance separating the two probes (R); Ro 
is the Förster distance, that is, the distance between the donor and acceptor 
probe at which the energy transfer is (on average) 50% efficient.  
 
Fig. 3.3.c-2: (next page) Molecular structures and absorption/fluorescence spectra in 
aqueous buffer of the fluorescein derivative (6-carboxyfluorescein - FAM) 
used as donor and of  the tetramethylrhodamine derivative (5-
carboxytetramethylrhodamine - TAMRA) used as acceptor in the FRET 
experiments reported in this thesis.  
 
(a) 
(b) 
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The donor-acceptor pair used in the FRET experiments reported in this thesis is composed by 
a fluorescein derivative (6-carboxyfluorescein - FAM) as donor and a tetramethylrhodamine 
derivative (5-carboxytetramethylrhodamine - TAMRA) as acceptor (Mergny et al. 2001). 
Their structures and absorption/fluorescence spectra in aqueous buffer are reported in Fig. 
3.3.c-2.  
The two probes are linked (by mean of a C-6 linker) to the ends of the used oligonucleotides 
and detection is made on quenching of donor fluorescence, so that during DNA melting an 
increase of fluorescence is observed, due to the increasing of the distance between the two 
probes, that are instead close enough to give efficient FRET when DNA is annealed.  
 
Oligonucleotides: Two different fluorescent conjugated oligonucleotides were used as models 
for intramolecular G-quadruplex and duplex DNA respectively. Both of them were purchased 
from Oswel (Southampton, UK). G-quadruplex forming sequence was 5’-FAM-
dGGG(TTAGGG)3-TAMRA-3’ (F21T), while duplex model was 5’-FAM-dTATAGCTATA-
(CH2-CH2-O)6-dTATAGCTATA-TAMRA-3’ (F10D). DNA was initially dissolved as a stock 
20µM solution in 10mM TE (Tris, EDTA) buffer (pH 8.0); further dilutions were carried out 
in 50mM potassium cacodylate buffer (pH 7.4).  
 
Drugs stocks preparation: Drugs were dissolved in bidistilled water, so that to obtain 1mM 
stocks; further dilutions were carried out in 50mM potassium cacodylate buffer (pH 7.4). 
Stocks were used within 72 hours from their preparation. They were kept at +4°C, avoiding 
light exposure. 
 
FRET stabilisation assay: The ability of the compounds to stabilize intramolecular G-
quadruplex and duplex DNA was investigated using a FRET assay modified to be used in a 
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96-well format. Oligonucleotides were diluted in the relevant buffer to the 2x concentration 
(400nM) and then annealed by heating to 85°C for 5 minutes, followed by cooling to room 
temperature in the heating block.  
96-well plates (MJ Research, Waltham, MA) were prepared by aliquoting 50µL of the 
annealed DNA to each well, followed by 50µL of the compound solutions. Samples were left 
equilibrating for half an hour before starting the experiment. Measurements were made on a 
DNA Engine Opticon (MJ Research) with excitation at 450-495nm and detection at 515-
545nm. Fluorescence readings were taken at intervals of 0.5°C over the range 30-100°C, with 
a constant temperature being maintained for 30 seconds prior to each reading to ensure a 
stable value. Final analysis of the data was carried out using a script written in the program 
Origin 7.0 (OriginLab Corp., Northampton, MA). 
Drug concentrations were chosen so that to have the final drug/DNA ratios (R) as reported in 
the following table.  
 
All the experiments were carried out in triplicate. Maximum drug concentrations were proven 
not to have enough fluorescence on their own to disturb fluorescence of the probes. Where 
necessary DMSO stocks were used, with a final DMSO concentration less than 0,5% not 
affecting DNA stability. The poor fluorescence of berberine and piperidin-berberine allowed 
to reach drug concentrations of 5 and 10µM (R=25 and 50 respectively) for these compounds. 
conc.(µM)  0.02 0.04 0.06 0.10 0.15 0.20 0.40 0.60 1.00 1.50 2.00 
R  0.10 0.20 0.30 0.50 0.75 1.00 2.00 3.00 5.00 7.50 10.00 
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3.3.d. Telomeric Repeat Amplification Protocol (TRAP) assays 
 
In order to study the ability of the considered compounds to inhibit telomerase, two different 
telomeric repeat amplification protocol (TRAP) assays were considered. Its schematic 
principles are reported in Fig. 3.3.d-1. First, the standard not telomeric TS oligonucleotide 
(5’-AATCCGTCGAGCAGAGTT-3’) was used as telomerase substrate (Kim et al. 1994): 
because of the specific feature of this sequence, TRAP only allows the detection of G-
quadruplex-induced telomerase inhibition after the synthesis of at least two or four telomeric 
repeats. TRAP assays were repeated using TSG4  oligonucleotide (par. 3.3.a) as telomerase 
substrate (Gomez et al. 2002): it is able to form intramolecular G-quadruplex also before the 
telomerase synthesis. In fact, the KCl concentration used in the TRAP assay (68mM) allows 
the formation of G-quadruplex by TSG4. Nevertheless, a similar structure is not so stable and 
in the absence of a G-quadruplex stabilizing molecule, it may be efficiently unfolded and 
extended by telomerase (Rossetti et al. 2004). 
In all cases, drugs were added at different concentrations to the reaction mixture (50µL), that 
contains 50µM dNTPs, 0.5µM TS primer, 1µL of cell extract (prepared from 109 cultured 
HeLa cells, as previously described (Kim et al. 1994)) in TRAP buffer (20mM Tris-HCl (pH 
7.5), 68mM KCl, 15mM MgCl2, 10mM EDTA, 0.5% Tween20). Samples were incubated for 
2 hours at 30°C, before the addition of the cell extract. After 30 minutes of incubation at 
30°C, the samples were purified by phenol/chloroform extraction. 32P radiolabeled TS (or 
TSG4), 0.5µM ACT (or CXext respectively, Gomez et al. 2002) primer (Kim et al. 1997) and 
2U Taq DNA polymerase (Eppendorf) were added and 27 PCR (Polymerase Chain Reaction) 
cycles were performed (94°C 30”, 50°C 30”, 72°C 1’30”). This technique allows obtaining 
large amounts of DNA copies starting from small amounts of an initial sequence, which is 
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Fig. 3.3.d-1: Telomeric Repeat Amplification Protocol (TRAP) assays. Telomerase can 
add sequences of six nucleotides, starting from a suitable substrate, so that 
to give a ladder when the products of elongation are loaded on 
polyacrylamide gel (left lane). In the presence of a molecule able to 
induce and/or stabilize G-quadruplex structures in telomeric sequences, 
telomerase cannot bind to its substrate and the result is a weaker and 
shorter ladder (right lane).  
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amplified by DNA polymerase, if suitable complementary primers are provided. Finally, the 
samples were loaded on non-denaturing 12% polyacrylamide gel. As references, a sample in 
which no drug was added,  one where cell extract was not added and one in which heat 
inactivation was performed by heating 10µL extract at 75°C for 10 minutes, prior to assaying 
1µL by TRAP analysis, were considered. A 130bp “internal standard” (IS) was used to 
control the PCR amplification efficiency (Gan et al. 2001). 
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3.4. Molecular modeling 
 
All the experiments were performed using the InsightII package on an SGI workstation. This 
software is widely used for the modeling of protein-ligand complexes, and more rarely for 
DNA-ligand complexes (Osiadacz et al. 2000).  
The G-quadruplex structure used in all the simulations is the X-ray derived monomeric 
structure of the 22-mer human telomeric DNA sequence AGGG(TTAGGG)3, 1KF1 code in 
the PDB (Fig. 1.2-5, Parkinson et al. 2002).  The PDB coordinates file was imported into the 
InsightII modeling package; the potassium ions in the central channel between the planes of 
each G-quartet were preserved, while all water molecules were deleted. Hydrogen atoms were 
added to the structure and potentials and partial charges were assigned according to the CVFF 
force-field, considering a pH of 7.0. A +1 partial charge was assigned to each potassium ion. 
Ligand molecules were built using the Builder module in InsightII. Nitrogen atoms in the side 
chains were protonated assigning a +1 formal charge (except for PIPER2, no charge, and 
PIPER3, par. 4.5) and CVFF force-field atom and bond types were assigned to all the 
structures (except for PIPER7, for which CFF parameters were necessary). All the structures 
were energy-minimized (2000 steps, Polak-Ribiere conjugate gradient) using the Discover_3 
module.  
Docking was performed in two phases with the Affinity Docking module of InsightII. The 
binding pocket was defined as all and only H atoms on the guanine bases of the external G-
quartet planes (one of the two possible external planes at a time, par. 4.5). In the first phase 
200 ligand orientations were randomly centred on the G-quadruplex structure. In this phase 
charges were not considered, non-bonded cut-offs were set to 8Å and Van der Waals radii to 
10% of the full value. The complexes were minimized for 500 steps using Polak-Ribiere 
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conjugate gradient method; energy tolerance and energy range were set respectively to 10000 
and 40kcal/mol. In the second phase, the 75 lowest energy structures were used to perform 
simulated annealing. During this phase Van der Waals radii were adjusted to their full values 
and a distance-dependent dielectric constant of 4.0 was used. Each system was again 
minimized for 500 steps of conjugate gradient and then molecular dynamics was performed, 
starting at a temperature of 800K and cooling the system to 200K over a period of 10ps. The 
resulting structures were minimized for 2000 steps of conjugate gradient and the 25 structures 
with the lowest total energies were evaluated with the Analysis module of InsightII. The 
Docking module was used to calculate the intermolecular (binding) energy, obtained as a sum 
of electrostatic and Van der Waals contributions, between drug and DNA, setting cut-offs to 
100Å. 
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4. Results 
 
4.1. Investigated compounds and their physico-chemical 
properties 
 
4.1.a. Perylene and coronene derivatives 
 
All perylene and coronene derivatives studied in this thesis are reported in Fig. 4.1.a-1, their 
synthesis is described in chapter 3.1, or otherwise their commercial source is indicated.  
Simple perylene diimides have been widely studied (Fedoroff et al. 1998, Han et al. 1999, 
Rossetti et al. 2002, Kerwin et al. 2002, Kern et al. 2002, Rossetti et al. 2004), since PIPER 
has been known for several years for its ability in inducing G-quadruplex structures and in 
inhibiting telomerase (par. 1.6.a). In this series of compounds, maintaining unchanged the 
stacking interactions due to the perylene aromatic core, it is possible to compare the effect of 
different side chains linked to the same aromatic moiety. In particular, PIPER side chains are 
characterized by a nitrogen atom in a piperidine ring (pKa≈11), so that it can be considered 
totally charged, in the adopted experimental conditions (pH 6.5 and 7.5). In the case of 
PIPER2, instead, the nitrogen atom in the aromatic pyridine ring (pKa≈5.5) is positively 
charged only in a small fraction of the molecules, in the same conditions. The piperazine ring 
of PIPER3 has two nitrogen atoms, whose first dissociation constant is comparable to that of 
PIPER, while the second one is comparable to that of PIPER2, so that a small fraction of 
molecules will be doubly charged in the experimental conditions around neutrality, while in 
the molecules with a single charge, it can be positioned alternatively on one of the two 
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nitrogen atoms; furthermore, the possibility exists to make different hydrogen bonds with 
DNA phosphates than PIPER. Two compounds have a morpholine ring in the side chains: 
PIPER4 and PIPER5; the expected pKa for these compounds is about 8. They have ethyl and 
propyl linkers respectively to connect the morpholine N atom to the aromatic moiety; the 
oxygen atom on the morpholine ring leads to a greater polar chain than all the other 
considered compounds, except PIPER3. PIPER6 and PIPER7 have not the charged nitrogen 
atom directly linked to the side chain; both of them have an ethyl linker and the expected pKa 
for PIPER6 is about 10. This means that the distance of the nitrogen atom from the aromatic 
core is roughly the same as in the case of PIPER5, that is characterized by a propyl linker. 
This is also the case of DAPER, whose nitrogen atom in the side chains even having pKa 
comparable to that of PIPER, is not inside a cycle, so that its charge has a different 
stereochemistry. 
The “self-aggregation” process of the perylene diimides, due to the stacking interactions 
between drug molecules, deeply influences both their interactions with the G-quadruplex 
(even though the mechanism has not been fully understood) and their water solubility 
(Rossetti et al. 2004, Kerwin et al. 2002, Kern et al. 2002). In Fig. 4.1.a-2 (top) the UV/Vis 
absorption spectra of PIPER in organic solvent (DMSO) and water are reported. A strong 
hypochromic effect can be observed in aqueous solution, suggesting a “self-association” 
process, which is confirmed by the poor resolution of the respective aromatic NMR signals. 
The other perylene diimides present identical UV/Vis spectra in DMSO, with peaks at 462, 
493 and 529nm, whose intensities are equal for all the different compounds (Fig. 4.1.a-2 
(bottom)), while the spectra in aqueous solution show a strong hypochromic effect, but to a 
different extent, depending on the different side chains (Fig. 4.1.a-3). This clearly indicates 
that the “self-aggregation” process depends on the different side chains, and it is probably 
mainly related to their different basicity. In Fig. 4.1.a-3, representative PIPER (A) and 
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Fig. 4.1.a-2: UV/Vis absorption spectra of PIPER in DMSO (red) and water (blue) and the 
respective aromatic protons signals by NMR (top). Perylene derivatives UV/Vis 
absorption spectra in DMSO (bottom).  
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Fig. 4.1.a-3: Visible absorption spectra of serial dilutions of three perylene derivatives, PIPER, 
PIPER3 and PIPER4 in 10 mM MES buffer pH 6.5 (respectively A, B and C) and in 
TRAP buffer pH 7.5 (respectively D, E and F). The concentrations of the drugs 
solutions are in the range of 5-50 µM, the higher extinction coefficients corresponding 
to the more dilute solutions. The arrow indicates the isobestic point. 
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PIPER4 PIPER4 
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PIPER3 (B) spectra in MES buffer (pH 6.5, par. 3.3.a) are reported. The spectra have a 
maximum at 500nm with a shoulder at 540nm and an isobestic point at 550nm; the presence 
of one isobestic point suggests that there is an equilibrium between a monomeric and a 
multimeric drug form (Rossetti et al. 2004). PIPER4 and PIPER5 spectra are different 
considering three main features: (i) the isobestic point is absent, (ii) the hypochromic effect is 
larger than in the case of the other four derivatives and (iii) the peak at 500nm is substituted 
by a broad band centred at about 470nm (representative PIPER4 spectrum is reported in Fig. 
4.1.a-3(C)). All these features seem consistent with the formation of more than one type of 
multimeric aggregates. All these absorption spectra were measured also in TRAP buffer at pH 
7.5 (par. 3.3.a). In these experimental conditions the absorption spectrum of PIPER (Fig. 
4.1.a-3(D)) becomes very similar to those of PIPER4 and PIPER5,  while the absorption 
spectra of the other perylene derivatives are basically unchanged (in Fig. 4.1.a-3 
representative PIPER3 (E) and PIPER4 (F) spectra are reported). In all cases an increasing of 
the molar extinction coefficient when decreasing drug concentration can be observed, 
suggesting a decreasing of the self-association process due to dilution (Rossetti et al. 2004).  
In order to obtain more water-soluble perylene derivatives, as well as to study the effect of 
changing the aromatic conjugation in this class of molecules, the synthesis of the new 
perylene derivatives PIP-PIPER and MORPHO-PIPER (in their different isomeric forms) was 
carried out (Fig. 4.1.a-1, par. 3.1.b). These new compounds show a very high water solubility, 
as expected, so that it was even difficult to precipitate the corresponding hydrochloride salts 
with the simple adding of acetone, as for previous perylene derivatives, and another efficient 
method was used (par. 3.1.b). The effect of the conjugation of the new nitrogen atoms inserted 
on the perylene bay-area is evident by comparing their absorption spectra with those of 
perylene derivatives that have not this conjugation. In fact, the absorption spectra of 
compounds 4a(I), 4b(I) and 4b(II), performed in chloroform and reported in Fig. 4.1.a-4(A), 
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Fig. 4.1.a-4: UV/Vis absorption spectra in CHCl3 of PIPER-Br (3) (────), MORPHO-
PIPER(1,6) [4b(II)] (- - - - -), PIP-PIPER(1,6) [4b(I)] (− · − · −) and PIP-
PIPER(1,7) [4a(I)] (− − − −) (A). UV/Vis absorption spectra in DMSO of 
CORON (6) (B).  
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show a broad band between 500 and 800nm, that is not present in the spectrum of PIPER-Br 
(3). This is due to the conjugation of the N atom of the piperidine or morpholine ring and the 
aromatic core of perylene, to which it is directly linked. This leads to an interesting chromatic 
change from the typical red colour of PIPER-Br (3) (analogous to that of 3,4,9,10-
perylenetetracarboxylic dianhydride and previously derived perylene diimides) to the green 
colour of 4a(I) and the blue of 4b(I) and 4b(II). It is also interesting to note that the colour of  
each compound depends on the relative positions of the two nitrogen atoms directly  linked to 
the aromatic core: the (1,7) isomer is green, while the (1,6) isomers are blue, regardless of the 
different kind of cyclic ammine (Franceschin et al. 2004).  
Structural studies on the perylene diimides and many other G-quadruplex interactive 
compounds, both by NMR and molecular modeling, are based on the model of “threading 
intercalation”. According to this model (par. 1.6), proposed in particular by Hurley and 
coworkers (Fedoroff et al. 1998) for PIPER, it is possible to suppose that a wider aromatic 
core and four positively charged side chains should improve the interactions between these 
ligands and the G-quadruplex, leading to higher binding constants and consequently to 
increased telomerase inhibition. In order to obtain a new molecule with these two molecular 
features, the synthesis of the new hydrosoluble coronene derivative CORON (6) was carried 
out (par. 3.1.c). The UV/Vis spectrum of CORON (6) in DMSO shows the characteristic five 
bands between 350 and 550nm of coronene (Fig. 4.1.a-4(B), Rohr et al. 1998, Rohr et al. 
2001). The visible absorption spectra of serial dilutions of CORON hydrochloride in MES 
buffer (pH 6.5) and in TRAP buffer (pH 7.5), in the range of 5-50 µM (Fig. 4.1.a-5), show a 
minor resolution of the bands and a strong hypochromic effect with respect to the DMSO 
spectrum, similarly to what has been observed in the case of perylene derivatives. In 
particular, in this case no isobestic point can be observed, suggesting the formation of more 
than one type of multimeric aggregates. 
 86 
 
Wavelength (nm) 
0 
10 
15 
20 
25 
30 
350 400 450 500 550 600 
ε 
· 
10
-
3  
(m
o
l-1
 
cm
-
1  
l) 
5 
CORON in MES buffer (pH 6.5) 
Wavelength (nm) 
0 
10 
15 
20 
25 
30 
350 400 450 500 550 600 
ε 
· 
10
-
3  
(m
o
l-1
 
cm
-
1  
l) 
5 
CORON in TRAP buffer (pH 7.5) 
Fig. 4.1.a-5: Visible absorption spectra of serial dilutions of CORON hydrochloride 
in MES buffer (pH 6.5, top) and in TRAP buffer (pH 7.5, bottom). Drug 
concentrations are in the range of 5-50 µM. 
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4.1.b. Berberine analogues and derivatives 
 
Berberine is an alkaloid that has been recently shown to be able to inhibit telomeres 
elongation (Naasani et al. 1999) and to bind to G-quadruplex DNA (Ren et. al. 1999, par. 
1.6.b).  
After considering perylene and coronene synthetic derivatives, it was interesting to examine 
the activity of this natural compound, whose aromatic moiety is suitable for stacking 
interaction with the G-tetrad and, probably due to the presence of a positive charged nitrogen 
atom, is able to induce and bind to G-quadruplex DNA, even without side chains. Also its 
commercially available analogue coralyne was shown to bind to quadruplex and tetraplex 
DNA (Ren et. al. 1999). So, on these bases, the new piperidin-berberine derivative was 
synthesized (Fig. 4.1.b-1, par. 3.1.d). This compound represents a sort of molecular chimera, 
in which a side chain analogue to that of PIPER has been attached to the aromatic moiety of 
berberine. These molecules represent a new class of G-quadruplex interacting compounds and 
telomerase inhibitors, structurally related to natural products. 
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Fig. 4.1.b-1: Berberine analogues and derivatives studied in this thesis. 
 
 
 89 
4.2. Induction of G-quadruplex structures in telomeric sequences: 
perylene diimides with different side chains are selective in 
inducing different G-quadruplex DNA structures 
 
The role of the different side chains of perylene derivatives in the formation of inter- and 
intramolecular G-quadruplex structures was investigated by PAGE (PolyAcrylamide Gel 
Electrophoresis), according to the experimental procedure described in par. 3.3.a. The DNA 
oligonucleotides 2HTR and TSG4 were used in these experiments (Rossetti et al. 2002, 
Rossetti et al. 2004): 2HTR (5’-AATCCGTCGAGCAGAGTTAGGGTTAGGGTTAG-3’) is 
formed by the TS sequence (that is the usual primer for telomerase elongation, par. 3.3.d) 
followed by two human telomeric repeats, it is able to form only dimeric and/or tetrameric 
intermolecular G-quadruplex structures; TSG4  (5’-GGGATTGGGATTGGGATTGGGTT-
3’) forms preferentially intramolecular G-quadruplex structures and can act as a substrate for 
telomerase elongation in a modified  TRAP assay (Gomez et al. 2002, Rossetti et al. 2004, 
par. 4.4). They were incubated with all perylene derivatives at increasing concentration and 
the formation of G-quadruplex structures was investigated by PAGE analysis (Fig. 4.2-1/4). 
Considering previous gel shift data obtained in similar experimental conditions (Han et al. 
1999) and the mobility standard obtained by G-quadruplex dimeric forms induced by the 
potassium ions (Fang et al. 1993), major electrophoretic bands are identified as single 
stranded DNA (ss), dimeric (D), tetrameric (T) and monomeric (M) G-quadruplex structures. 
Intramolecular structure (M) corresponds to the highest mobility band: in fact, its particular 
structure favours the running in the gel grid also with respect to single stranded DNA 
(Henderson et al. 1987, Williamson et al. 1989). To better compare the different behaviour of 
the different molecules, the percentage of the induced G-quadruplex structures has been 
reported as a function of drugs concentration (Fig. 4.2-1/4). 
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The most striking aspect that emerges from the results obtained using 2HTR oligomer and 
reported in Fig. 4.2-1 is that, although PIPER2 should be able to establish stacking 
interactions with the G-tetrads, the strong decrease of electrostatic interactions with the DNA 
grooves due to the weak basicity of pyridine nitrogen atoms does not allow the formation of 
G-quadruplex structures. On the other hand, through the quaternization of the nitrogen atom 
on the pyridine ring (par. 3.1.a), PIPER7 achieves a fully charged nitrogen atom and shows an 
activity comparable to the best perylene derivatives. In fact, the obtained results reported in 
Fig. 4.2-2, using 2HTR oligomer in MES buffer pH 6.5, KCl 50mM, show that all the other 
perylene derivatives are almost equally able to induce intermolecular G-quadruplex structures, 
except PIPER4, that is definitively less efficient. Furthermore, PIPER is the only perylene 
derivative able to induce a G-quadruplex structure that involves four strands, while it is barely 
efficient in inducing dimers (Fig. 4.2-1/2). To study the effect of the different perylene 
derivatives in the formation of intramolecular G-quadruplex, TSG4 oligonucleotide was used. 
In this case, incubating the samples in the presence of KCl 5mM (in this experimental 
conditions no G-quadruplex structure is formed in drug absence), all perylene derivatives are 
able to induce intramolecular G-quadruplex, corresponding to a high mobility electrophoretic 
band (Fig. 4.2-2(B,D)). It is worth noting that PIPER4 induces intramolecular G-quadruplex 
structures only at a drug concentration higher than those considered (data not shown), since 
the intermediate bands, evidenced at lower concentrations, can not be considered as canonical 
intramolecular G-quadruplex. Performing the same experiment in the presence of KCl 50mM, 
the monomeric G-quadruplex structure is formed also in absence of any drug. In these 
conditions, all perylene derivatives bind to the preformed intramolecular G-quadruplex 
structure, slightly varying its mobility (Fig. 4.2-3). 
To take into account the different basicity of drugs side chains, which is surely important for 
the interactions with G-quadruplex structures, electrophoretic mobility shift assays were 
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Fig. 4.2-1: G-quadruplex structures formation induced by PIPER, PIPER2, PIPER3 and 
DAPER (Fig. 4.1.a-1), studied by native PAGE (PolyAcrylamide Gel 
Electrophoresis) according to the experimental procedure described in par. 3.3.a. 
(a) 8 µM 2HTR was incubated in MES-KCl buffer (pH 6.5) in the presence of 
different drugs concentrations: 5 µM (lane 1), 10 µM (2), 30 µM (3), 50 µM (4), 
70 µM (5), 100 µM (6), 130 µM (7) and with no drug (lane 0). In lane K, 2HTR 
was incubated with KCl 1 M. Major bands are identified as single stranded DNA 
(ss), dimeric (D) and tetrameric (T) G-quadruplex structures. (b) Percentage of G-
quadruplex structures formed (Gq%) versus drug concentration (C) of PIPER, 
PIPER3 (♦) and DAPER (∆). In the case of PIPER, dimeric (●) and tetrameric (○) 
structures can be distinguished (the dashed line being their sum). In this plot, the 
values corresponding to concentrations higher than 70 µM have not been 
considered because of the increasing amount of higher-order structures. Gq% 
represents the ratio between the intensity of the relative band on the 
electrophoresis gel and the total amount of DNA, obtained by Instant Imager 
(Rossetti et al. 2002).  
C (µM) 
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Fig. 4.2-2: G-quadruplex structures formation induced by the six perylene derivatives indicated, whose 
structures are reported in Fig. 4.1.a-1, studied by native PAGE (PolyAcrylamide Gel 
Electrophoresis) according to the experimental procedure described in par. 3.3.a. A) 2HTR 
(12 µM) was incubated in MES-KCl buffer (pH 6.5) in the presence of different drugs 
concentrations: 10 µM (lane 1), 20 µM (2), 30 µM (3), 40 µM (4), 50 µM (5) and with no 
drug (lane 0). B) TSG4 (12 µM), in 10 mM MES, pH 6.5, 5 mM KCl, was incubated, as 
described above for 2HTR, in the presence of different drugs concentrations: 5 µM (lane 1), 
10 µM (2), 20 µM (3), 30 µM (4), and with no drug (lane 0). Major bands are identified as 
single stranded DNA (ss), dimeric (D), tetrameric (T) and monomeric (M) G-quadruplex 
structures. C-D) Percentage of G-quadruplex structures formed (Gq%, see the caption of 
Fig. 4.2-1) in function of drug concentration (C (µM)) relative to the band shift assays 
reported in A) and in B) respectively. In the case of PIPER, intermolecular dimeric (PD) and 
tetrameric (PT) structures can be distinguished (the dashed line being their sum (P)). 
Intermediate bands between ss and M in (B) were not considered when calculating values 
reported in (D) (Rossetti et al. 2004).  
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Fig. 4.2-3: G-quadruplex structures formation studied by native PAGE on TSG4 oligonucleotide 
in MES-KCl buffer (10 mM MES, pH 6.5, 50 mM KCl). 12 µM TSG4 was incubated 
in MES-KCl buffer in the presence of different drugs concentrations: 10 µM (lane 1), 
20 µM (2), 30 µM (3), 40 µM (4), 50 µM (5) and with no drug (lane 0). It is evident 
the formation of monomeric G-quadruplex also in the absence of any drug (lane 0), 
differently from what happens at 5 mM KCl (Fig. 4.2-2(B)). 
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repeated in the same experimental conditions, except that TRAP buffer pH 7.5 was used (Fig. 
4.2-4). Both PIPER4 and PIPER5 are unable to induce appreciable amount of intermolecular 
G-quadruplex structure (2HTR), while the behaviour of the other perylene derivatives is 
basically unchanged (Fig. 4.2-4(A,C)). Considering the formation of intramolecular G-
quadruplex structure (TSG4), all perylene derivatives start to induce intramolecular G-
quadruplex at higher concentration (Fig. 4.2-4(B,D)) with respect to the experiments carried 
out at pH 6.5 (Fig. 4.2-2(B,D)); also in this case, PIPER 4 and PIPER5 result the less efficient 
drugs, being unable to induce a canonical intramolecular G-quadruplex structure at the 
considered drugs concentrations. 
 
 95 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0 10 20 30 40 
60 
100 
20 
0 
40 
80 
C (µM) 
%
 
G
-
Qu
ad
ru
pl
ex
 
 
(G
q 
%
) 
P6 
P4, P5  
P 
P3, P7 
P 
PT 
P3, P6, P7 
PD 
P4, P5  
C (µM) 
%
 
G
-
Qu
ad
ru
pl
ex
 
 
(G
q 
%
) 
0 10 20 30 40 50 60 
60 
100 
20 
0 
40 
80 
ss 
D 
T 
   0          1     2     3      4      5     6     1      2      3     4     5    6              0      1     2     3     4     5     6       1      2     3    4      5     6              0        1      2      3      4      5      6      1      2      3     4      5     6 
             PIPER4                    PIPER5                     PIPER                   PIPER3                     PIPER6                       PIPER7 
                  PIPER6                    PIPER7         PIPER4                  PIPER5              PIPER                  PIPER3 
  0   1         2         3         4        1          2         3        4                 0         1          2        3         4           1         2         3         4                0        1         2          3          4          1         2         3        4 
M 
ss 
A) 
B) 
C) D) 
Fig. 4.2-4: G-quadruplex structures formation induced by the six perylene derivatives indicated, whose 
structures are reported in Fig. 4.1.a-1, studied by native PAGE; for details see the caption of 
Fig. 4.2-1/2. Samples containing 2HTR (A) or TSG4 (B), were incubated as described in 
the legend of Fig. 4.2-2 except that they were incubated in TRAP Buffer, pH 7.5 (20 mM 
Tris-HCl (pH 7.5), 15 mM MgCl2, 10 mM EDTA, 0.5% Tween20), 50 mM KCl in the case 
of 2HTR and 5 mM KCl in the case of TSG4, in the presence of different drugs 
concentrations: 5 µM (lane 1), 10 µM (2), 20 µM (3), 30 µM (4), 40 µM (5) and 50 µM (6) 
and with no drug (lane 0). C-D) Percentage of G-quadruplex structures formed (Gq%) in 
function of drug concentration (C (µM)) of the six perylene derivatives, relative to the band 
shift assays reported in A) and in B) respectively (Rossetti et al. 2004).  
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4.3. Stabilization of preformed G-quadruplex and duplex DNA 
structures 
 
4.3.a. FRET assays on a monomeric G-quadruplex 
 
Fluorescence energy transfer can be used to reveal the formation of four-stranded DNA 
structures, and its stabilization by quadruplex-binding agents, as discussed in par. 3.3.c and 
reported by Mergny and coworkers (Mergny et al. 2001, Koeppel et al. 2001). 
Curves obtained by FRET experiments on F21T sequence, performed as described in par. 
3.3.c, are reported in Fig.4.3.a-1. R is the drug/DNA ratio defined as the ratio between the 
molar drugs concentration and the molar DNA concentration, expressed in oligonucleotides 
molecules. F21T is a 21-mer human telomeric sequence [GGG(TTAGGG)3], whose ends are 
labelled by two fluorescent probes that form an acceptor/donor system (par. 3.3.c, Mergny et 
al. 2001). The experimental conditions are identical to those used for the crystallization of the 
sequence [AGGG(TTAGGG)3], whose structure was recently resolved as a new monomeric 
G-quadruplex structure (Parkinson et al. 2002).  
The change in shape of the melting curves when adding perylene derivatives suggests that, as 
a consequence of the binding with the drug molecules, the melting process looses its 
characteristic cooperativity and, at high R values, two melting steps appear in most cases. 
Nevertheless, the interactions between perylene derivatives and G-quadruplex seem to be very 
strong, with significant effects starting from very low concentrations (R=0.5).  
It’s interesting to note that most of perylene derivatives reach a sort of “saturation” at R=2; 
this could be due to the presence of two possible binding sites for each G-quadruplex: 5’ and 
3’ external G-quartet planes. The appearance of two melting steps, quite evident in the case of 
 97 
 
T (°C) 
30 40 50 60 70 80 90 100
0.0
0.2
0.4
0.6
0.8
1.0
T
F
PIPER3
 0
 0.10
 0.20
 0.30
 0.50
 0.75
 1.00
 2.00
 3.00
 5.00
 7.50
 10.0
30 40 50 60 70 80 90 100
0.0
0.2
0.4
0.6
0.8
1.0
PIPER5
F
T
 0
 0.10
 0.20
 0.30
 0.50
 0.75
 1.00
 2.00
 3.00
 5.00
 7.50
 10.0
T (°C) 
30 40 50 60 70 80 90 100
0.0
0.2
0.4
0.6
0.8
1.0
PIPER
F
T
 0
 0.10
 0.20
 0.30
 0.50
 0.75
 1.00
 2.00
 3.00
 5.00
 7.50
 10.0
30 40 50 60 70 80 90 100
0.0
0.2
0.4
0.6
0.8
1.0
T
F
PIPER4
 0
 0.10
 0.20
 0.30
 0.50
 0.75
 1.00
 2.00
 3.00
 5.00
 7.50
 10.0
30 40 50 60 70 80 90 100
0.0
0.2
0.4
0.6
0.8
1.0
F
T
 0
 0.10
 0.20
 0.30
 0.50
 0.75
 1.00
 2.00
 3.00
 5.00
 7.50
 10.0
PIPER6
30 40 50 60 70 80 90 100
0.0
0.2
0.4
0.6
0.8
1.0
F
T
PIP-PIPER
(isomero verde)
 0
 0.20
 0.50
 1.00
 2.00
 3.00
 5.00
 7.50
 10.0
30 40 50 60 70 80 90 100
0.0
0.2
0.4
0.6
0.8
1.0
PIPER7
F
T
 0
 0.10
 0.20
 0.30
 0.50
 0.75
 1.00
 2.00
 3.00
 5.00
 7.50
 10.0
PIP-PIPER 
(1,7) 
Fig. 4.3.a-1 (continues in the next page) 
 
30 40 50 60 70 80 90 100
0.0
0.2
0.4
0.6
0.8
1.0
DAPER
quadr2
F
T
 0
 0.10
 0.20
 0.30
 0.50
 0.75
 1.00
 2.00
 3.00
 5.00
 7.50
 10.0
T (°C) 
T (°C) 
T (°C) T (°C) 
T (°C) T (°C) 
 98 
 
30 40 50 60 70 80 90 100
0.0
0.2
0.4
0.6
0.8
1.0
Morpho-PIPER
F
T
 0
 0.20
 0.50
 1.00
 2.00
 3.00
 5.00
 7.50
 10.0
30 40 50 60 70 80 90 100
0.0
0.2
0.4
0.6
0.8
1.0
PIP-PIPER
(isomero blu)
F
T
 0
 0.20
 0.50
 1.00
 2.00
 3.00
 5.00
 7.50
 10.0
MORPHO-
PIPER (1,6) 
PI - IPER 
(1,6) 
30 40 50 60 70 80 90 100
0.0
0.2
0.4
0.6
0.8
1.0
BERBERINE
F
T
 0
 0.20
 0.50
 0.75
 1.00
 2.00
 3.00
 5.00
 7.50
 10.0
 25.0
 50.0
30 40 50 60 70 80 90 100
0.0
0.2
0.4
0.6
0.8
1.0
 0
 0.20
 0.50
 0.75
 1.00
 2.00
 3.00
 5.00
 7.50
 10.0
 25.0
 50.0
piperidn-
BERBERINE
F
T
piperidin-
BERBERINE 
30 40 50 60 70 80 90 100
0.0
0.2
0.4
0.6
0.8
1.0
F
T
CORON
 0
 0.10
 0.20
 0.30
 0.50
 0.75
 1.00
 2.00
 3.00
 5.00
 7.50
 10.0
30 40 50 60 70 80 90 100
0.0
0.2
0.4
0.6
0.8
1.0
CORALINE
F
T
 0
 0.10
 0.20
 0.30
 0.50
 0.75
 1.00
 2.00
 3.00
 5.00
 7.50
 10.0
CORALYNE 
Fig. 4.3.a-1: Curves obtained by FRET experiments on F21T sequence. Legends show the 
drug/DNA ratios (R) as reported in par. 3.3.c. F is the relative fluorescence 
obtained after normalization and T is the temperature.  
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PIPER7, agrees with this model, too. The complexity of the melting curves could be also 
related to the change in the self-aggregation state of the ligand molecules with the increasing 
of the temperature. 
Because of the biphasic nature of the FRET curves obtained in the case of perylene 
derivatives, it is not easy to determine the melting temperature of the drug-DNA complexes at 
each concentration, in particular at intermediate values of R. The presence of a first melting 
step could be due to an intermediate unfolding form, while it is reasonable to associate the 
second melting step to the final disruption of the G-quadruplex structure. For these reasons, in 
order to evaluate the different behaviour of the various drugs, the differences (∆T) between 
the temperature corresponding to the second inflection point at R=10 for each derivative and 
the melting temperature of G-quadruplex without drugs (57.6±0.4°C) are reported in Tab.4.3.  
 
 Table 4.3  
   
compound ∆T(°C) 
    
PIPER 33,2 ± 1,2 
PIPER3 36,3 ± 0,6 
PIPER4 22,2 ± 1,5 
PIPER5 16,3 ± 1,3 
PIPER6 36,4 ± 0,7 
PIPER7 34,8 ± 1,0 
CORON 36,4 ± 0,7 
PIP-PIPER(1,7) 18,7 ± 0,8 
PIP-PIPER(1,6) 19,5 ± 0,7 
Morpho-PIPER 18,4 ± 1,8 
DAPER 35.9 ± 0.7 
    
 
It is evident that PIPER4, PIPER5 and the new perylene derivatives PIP-PIPER and Morpho-
PIPER influence the G-quadruplex thermodynamic stability to a minor extent with respect to 
PIPER, PIPER3, PIPER6, PIPER7, DAPER and the new coronene derivative CORON. 
Differently from perylene derivatives, berberine derivatives (berberine, coralyne and 
piperidin-berberine) show a continuous increasing of the melting temperature with the 
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increasing of drug/DNA ratio; the melting process is cooperative and appears monophasic at 
all drugs concentrations. In this case it is therefore possible to calculate the melting 
temperature (Tm) at each drug concentration. Since berberine and piperidin-berberine do not 
show a significant intrinsic fluorescence, it was possible to reach a drug concentration of 
10µM, (R=50). A direct comparison of the increasing in the G-quadruplex melting 
temperature due to these two molecules is reported in Fig. 4.3.a-2. It is evident that the new 
added side chain increases the effect on G-quadruplex stability of the new compound 
piperidin-berberine with respect to natural berberine. Nevertheless, it is worth noting that 
coralyne, that has a fully aromatic core, is much more active than both the other two 
compounds (Fig. 4.3.a-3). In the case of coralyne, similarly to perylene derivatives, drug 
concentration was kept under 2µM because above this concentration the drug intrinsic 
fluorescence becomes significant. 
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Fig. 4.3.a-2: Melting temperatures for F21T at increasing concentrations of berberine and piperidin-berberine, as 
derived from the first derivative of the melting curves reported in Fig. 4.3.a-1.  
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coralyne, as derived from the first derivative of the melting curves reported in Fig. 4.3.a-1.  
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4.3.b. Preliminary studies of selective interactions of one perylene 
derivative for G-quadruplex DNA with respect to duplex DNA by 
absorption spectroscopy and circular dichroism 
 
The selectivity of G-quadruplex interacting compounds for G-quadruplex DNA with respect 
to duplex DNA is surely a topic of great interest for the possible biological applications of 
these molecules (Kerwin et al. 2002, Kern et al. 2002). As a preliminary study, UV/Vis 
absorption spectra of one perylene derivative (PIPER3) were performed in the presence of 
different concentrations of quadruplex and duplex DNA structures, as described in par. 3.3.b. 
The DNA/ligand ratio (R) is calculated considering phosphates concentration for both DNAs. 
The spectra reported in Fig. 4.3.b-1 (quadruplex) and 4.3.b-2 (duplex) show two interesting 
features: the increasing of the molar extinction coefficient and the change in the shape of the 
spectra, that become similar to those obtained for PIPER3 alone in organic solvent (see par. 
4.1) at increasing concentration of DNA. Moreover, in both cases isobestic points can be 
observed, indicating the existence of an equilibrium between different species in solution. At 
the same DNA/ligand ratio (R), the hyperchromic effect is larger for G-quadruplex with 
respect to duplex DNA structures, above all for high values of R, as clearly evident from the 
graph reported in Fig. 4.3.b-3, suggesting a high selectivity of PIPER3 for quadruplex with 
respect to duplex DNA.  
Another technique that appears suitable for this kind of study is circular dichroism (Cantor et 
al. 1980, p. 409). In fact, because of their symmetry, perylene derivatives do not show 
dichroic spectra, although they have a strong absorption in the visible region (see Fig. 4.1.a-
3). On the other hand, DNA alone does not present absorption bands in the visible region, so 
that the appearance of dichroic bands in this region when considering solutions at different 
drug/DNA ratios (Fig. 4.3.b-4) both for duplex and quadruplex DNA indicates that symmetric 
perylene chromophores interact with an asymmetric environment, represented by DNA 
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Fig. 4.3.b-1: Absorption spectra of samples containing PIPER3 10µM and 
oligonicleotide (T4G4)2 at different concentrations, in MES buffer 
(10mM, pH 6.5). (T4G4)2 was previously annealed in KCl 100mM. 
Thin arrows indicate isobestic points, large arrow indicates the 
increase in oligonucleotide concentration. 
0
10
20
30
40
50
350 400 450 500 550 600 650
Wavelength (nm) 
ε 
· 
10
-
3  
(m
o
l-1
 
cm
-
1  
l) 
 105 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
10
20
30
40
50
350 400 450 500 550 600 650
Wavelength (nm) 
ε 
· 
10
-
3  
(m
o
l-1
 
cm
-
1  
l) 
Fig. 4.3.b-2: Absorption spectra of samples containing PIPER3 10µM and canonical 
duplex DNA (Calf Thymus, CT) at different concentrations, in MES buffer 
(10mM, pH 6.5). Thin arrows indicate isobestic points, large arrow 
indicates the increase in oligonucleotide concentration. 
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Fig. 4.3.b-3: PIPER3 (10µM) molar extintion coefficient (548nm) versus DNA/ligand 
concentration ratio (R). Used DNA was duplex CT, dotted line, and 
quadruplex (T4G4)2, continuous line. R is calculated considering 
phosphates concentration for both DNAs. 
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structures. A complete titration in a suitable range of drug/DNA ratios and the consequent 
analysis could lead to a good approach for the evaluation and quantification of the interactions 
between drugs and different DNA structures. 
These preliminary results are surely encouraging and absorption spectroscopy techniques 
appear a good method to evaluate binding constants for perylene derivatives with quadruplex 
and duplex DNA. 
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4.3.c. FRET assays on an autocomplementary decamer 
 
Because of the great importance of the selectivity of the analysed drugs for G-quadruplex 
DNA with respect to duplex DNA, as discussed in the previous paragraph, the necessity to 
find a quicker method than the titrations of drugs binding sites carried out by absorption 
spectroscopy or circular dichroism emerges. Although the last ones are necessary to calculate 
the correct binding constants, a quicker evaluation of this selectivity could rely on using 
FRET techniques. If the same two fluorescent probes linked to the ends of the F21T 
oligonucleotide, used as G-quadruplex model, are linked to the ends of an autocomplementary 
sequence, according to the Watson and Crick base pairings, a method for the study of the 
interactions of the drugs with duplex DNA could be developed. In this case, it is necessary to 
define a “direction” of the sequence, so that the two fluorescent probes will be always at the 
same end of the DNA folded structure. It must be also considered that the unfolded structure 
would cause the separation of the two strands, differently from what happens in the case of 
monomeric G-quadruplex, since it consists of an intramolecular structure. In order to solve 
both these problems a polyethylenglycol linker was used to bind two autocomplementary 
decamer TATAGCTATA, with one probe at each end. For these reasons, the sequence F10D 
used in these FRET experiments was: 5’-FAM-dTATAGCTATA-(CH2-CH2-O)6-
dTATAGCTATA-TAMRA-3’. In this way, the folded structure, that is supposed to be a 
duplex DNA, will have the donor/acceptor system correctly positioned to give fluorescence 
transfer, while in the unfolded structure the two strands are always kept together, but the 
donor/acceptor distance is too large for energy transfer. The system so composed can seem 
quite different from a canonical duplex DNA, so that it was useful to try it on a classical DNA 
duplex binder as ethidium bromide (Cantor et al. 1980, p. 445). In Fig. 4.3.c-1 the results of 
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Fig. 4.3.c-1: Curves obtained by FRET experiments on F10D (top) and F21T (bottom) 
sequences at increasing concentrations of ethidium bromide. Legends show 
the drug/DNA ratios (R) as reported in par. 3.3.c. F is the relative 
fluorescence obtained after normalization and T is the temperature.  
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the FRET experiments with ethidium bromide at drug/DNA ratios up to 100 are reported. The 
melting curve of F10D without drug shows the typical sigmoid shape of a cooperative process 
and the corresponding melting temperature (Tm) is 60.7±0.4°C. Until R=10, a slight effect can 
be observed on the shape of the melting curves as an initial destabilizing effect that does not 
alter too much Tm values. Only at R = 25, 50 and 100, a net increasing of the melting 
temperature can be observed, with a ∆Tm of about +10°C at R=100. At the same 
concentrations, ethidium bromide show a similar behaviour with the G-quadruplex forming 
sequence F21T (Fig. 4.3.c-1, bottom): no significant effect until R=10 and increasing melting 
temperatures starting from R=25, with a maximum of about +15°C at R=100. This indicates 
that ethidium bromide can bind both to duplex and quadruplex DNA without particular 
selectivity for one of the two structures. These results agree with previous studies in which, 
although ethidium bromide has been reported to bind to G-quadruplexes, its affinity and 
specificity for this structure was found to be low (Perry et al. 1999). 
As for perylene derivatives, FRET experiments on F10D sequence were performed at the 
same drug/DNA ratios (R) used for F21T, and the curves obtained are reported in Fig.4.3.c-2. 
Maximum concentration is 2µM (R=10), because fluorescence of the perylene derivatives 
become significant above this concentration. It is worth noting that most of them show good 
interaction with G-quadruplex and even a sort of “saturation” under this concentration. On the 
contrary, with the major exception of PIPER7 and, to a minor extent, of DAPER (that is used 
for DNA precipitation, Liu et al. 1996), all the other perylene derivatives show poor 
interactions with F10D duplex model. According to these results, they seem to show a good 
selectivity for G-quadruplex with respect to duplex DNA, as already suggested by titration 
with absorption spectroscopy of PIPER3 (that is however one of the few compounds that are 
able to slightly increase the melting temperature of F10D). It is also worth noting that 
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Fig. 4.3.c-2 (continues in the next page) 
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Fig. 4.3.c-2: Curves obtained by FRET experiments on F10D sequence. Legends show the 
drug/DNA ratios (R) as reported in par. 3.3.c. F is the relative fluorescence 
obtained after normalization and T is the temperature.  
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berberine and piperidin-berberine do not show interaction with F10D even at 50:1 drug/DNA 
ratio (Fig.4.3.c-2). 
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4.4. Different efficiency of the perylene diimides in telomerase 
inhibition 
 
The efficiency of the studied compounds as telomerase inhibitors has been evaluated by 
Telomeric Repeat Amplification Protocol (TRAP) assays, as described in par. 3.3.d. The 
activity of a cellular extract containing telomerase on two different substrates has been 
evaluated at different drugs concentrations (Rossetti et al. 2002, Rossetti et al. 2004). In Fig. 
4.4-1, the results of the experiments performed using the standard not telomeric TS 
oligonucleotide are reported. It is worth noting that after the synthesis of two telomeric 
repeats the DNA fragments are very similar to the oligonucleotide 2HTR, that was used in the 
electrophoretic mobility shift assays. PIPER is able to inhibit telomerase starting from a 
concentration of 40µM, while PIPER4 and PIPER5 are unable to inhibit the enzyme even at 
higher concentration. In the case of PIPER3, PIPER6 and PIPER7, on the contrary, the 
intensity and the number of bands clearly decrease with respect to the control, at a drug 
concentration in the range of 5-10µM.  
TRAP assays were repeated using TSG4 oligonucleotide as telomerase substrate: it is able to 
form intramolecular G-quadruplex also before the telomerase synthesis. In fact, the KCl 
concentration used in the TRAP assay (68mM) allows the formation of G-quadruplex by 
TSG4 (Fig. 4.2-3). Nevertheless, a similar structure is not stable in the absence of a suitable 
concentration of G-quadruplex stabilizing molecules and it may be efficiently unfolded and 
extended by telomerase (Gomez et al. 2002). The obtained results, in the presence of different 
perylene derivatives, are similar to those obtained using TS oligonucleotide (Fig. 4.4-2). 
PIPER3, PIPER6 and PIPER7 result the most efficient perylene derivatives in inhibiting 
telomerase, being active at a drug concentration in the range of 5-10µM. 
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Fig. 4.4-1: Inhibition of human telomerase by different perylene derivatives, by Telomerase Repeat Amplification Protocol (TRAP) assay, using 
TS as substrate (par. 3.3.d). In lane 0 no drug was added, in lane R1 cell extract was not added, in lane R2 heat inactivation was 
performed by heating 10 µL extract at 75°C for 10 minutes prior to assaying 1 µL by TRAP analysis. The considered drugs 
concentrations were 10 µM (lane 1), 20 µM (2), 30 µM (3), 40 µM (4) and 50 µM (5). IS is a 130 bp “internal standard” to control 
the PCR amplification efficiency (Rossetti et al. 2004).  
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Fig. 4.4-2: Inhibition of human telomerase by different perylene derivatives, by Telomerase Repeat Amplification Protocol (TRAP) assay, 
using TSG4 as substrate (par. 3.3.d). The symbols used are the same as in Fig. 4.4-1. The considered drugs concentrations were 
5 µM (lane 1), 10 µM (2), 20 µM (3), 30 µM (4), 40 µM (5) and 50 µM (6). (Rossetti et al. 2004).  
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4.5. Structural models and energy calculations based on 
molecular modeling 
 
Simulated annealing experiments, performed as described in par. 3.4, led to a set of 25 
molecular structures for each studied compound, in which the ligand molecule is docked on 
the human G-quadruplex monomeric structure (Fig. 1.2-5, Parkinson et al. 2002). The 
corresponding intermolecular energy values were used to calculate the average binding 
energies (and the relative standard deviations) reported in Tab. 4.5. Repeated experiments 
show a good reproducibility, suggesting that the number of structures generated was sufficient 
to be statistically significant.  
Preliminary experiments performed on PIPER, using alternatively both external G-quartet 
planes of monomeric G-quadruplex structure to define the binding site, confirmed what was 
previously shown for acridine derivatives (Harrison et al. 2003): the best binding energy 
values are obtained when using the more hydrophilic 3’ G-quartet plane. If the hydrophobic 5’ 
G-quartet surface is used (deleting the potassium ion present on this face), absolute values of 
binding energy are about 10% lower than the ones obtained in the other case. Moreover, drug 
molecules show a wide range of different positions on the 5’ G-quartet surface: most of them 
have the side chains not fitted into the grooves but rather posed on the external phosphates 
backbone (Fig. 4.5-1). On the contrary, if the 3’ G-quartet plane is considered, all the 
structures obtained, apart from few exceptions, show drug molecules in one of the two 
possible orthogonal orientations, with the side chains pointing towards two opposite grooves 
(Fig. 4.5-2). For these reasons the 3’ G-quartet face was used as the binding site for the 
docking study of all the other compounds.  
 
 119 
 
Ligand Binding Energy Hbonds/structure 
 
  
PIPER (5') -860 ± 15 
 
0.16 
 
 
 
PIPER -925 ± 17 
 
0.16 
 
 
 
PIPER3(EXT) -998 ± 20 
 
1.24 
PIPER3(INT) -933 ± 13 
 
0.44 
PIPER3(MIX) -963 ± 22 
 
0.88 
PIPER3_medium      -964  
   
PIPER3(2CH) -1867 ± 22 
 
1.56 
   
PIPER2 -87 ± 5 
 
0.32 
PIPER4 -936 ± 14 
 
0.36 
PIPER5 -956 ± 21 
 
0.56 
PIPER6 -963 ± 12 
 
0.20 
PIPER7 -979 ± 12 
 
0.00 
DAPER -959 ± 15 
 
0.36 
 
 
 
PIP-PIPER (1,7) -937 ± 26 
 
0.36 
PIP-PIPER (1,6) -936 ± 24 
 
0.24 
MORPHO-PIPER (1,6) -944 ± 33 
 
0.40 
   
CORON -1729 ± 40 
 
0.28 
   
BERBERINE 
-432 ± 8 
 
0.00 
CORALYNE 
-455 ± 10 
 
0.00 
Piperidin-BERBERINE 
-862 ± 44 
 
0.20 
 
Tab.4.5 Binding energies for complexes between the human monomeric G-
quadruplex structure and the specified ligand, calculated as described 
in par. 3.4.  
 
Notes: 
- these calculations refer to the final 25 lowest energy structures for 
each experiment 
- all energy values are expressed in kcal/mol 
- (5’) indicates experiments in which the binding pocket has been 
defined on the 5’ G-quartet plane; in all the other simulations 3’ G-
quartet face was used 
- Hbonds/structure is the medium number of H-bonds per structure, 
calculated dividing the total number of H-bonds for the number of 
structures (25) 
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Fig. 4.5-2: The two possible orthogonal orientations of PIPER molecule 
(yellow) on the 3’ G-quartet face (DNA in blue). 
Fig. 4.5-1: PIPER molecule (yellow) stacked on the 5’ G-quartet surface 
(DNA in blue). Sticks and lines (left) and CPK model (right). 
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The case of PIPER3 is particular, since this molecule has a piperazine ring on the side chains; 
pKa values reported for the two N atoms of the piperazine ring are about 11 and 5 
respectively. This means that at a neutral pH only one nitrogen atom should be protonated on 
each ring; for this reason it was necessary to consider at least three different possible 
protonated forms for this molecule: the form with the two external (secondary) nitrogen atoms 
protonated (EXT), the form in which the protonated (tertiary) nitrogen atoms are internal 
(INT), and the form in which one is external and the other one internal (MIX). 
“PIPER3_medium” energy reported in Tab. 4.5 was calculated considering an occurrence of 
25% for “EXT” and “INT” forms and 50% for “MIX” form, for obvious statistical reasons. A 
possible but rather unlikely PIPER3 structure with two positive charges per ring was also 
considered (2CH). 
The main contribution to the binding energy is electrostatic, so that PIPER2 (no charge) has 
the lowest medium binding energy, while PIPER3(2CH) and CORON (4 charges per 
molecule, Fig.4.1.a-1) have the highest binding energies. It is worth noting that a PIPER3 
molecule with four charges is quite unlikely, while 4 charged CORON (1 positive charge per 
piperidine ring) should be the most usual state.  
Most of the structures obtained for PIPER on the 3’ G-quartet face show the ligand molecule 
in a position analogue to the one represented in Fig. 4.5-3: one side chain is well fitted into 
one of the four grooves (regardless of which one), while the other one is free to move, since it 
can’t reach the opposite groove. In someway the two chains seem to be too “short” to fit into 
both the opposite grooves simultaneously. Indeed DAPER and PIPER5, that have longer side 
chains than PIPER, manage to fit into them properly as shown in Fig.4.5-4. Binding energies 
for these compounds are actually slightly higher (in absolute value) than the ones for 
PIPER/PIPER4 (Tab. 4.5). This would suggest that the longer the chain, the better the binding 
to the G-quadruplex. Actually the fundamental parameter seems to be the distance between 
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Fig. 4.5-3: PIPER molecule (yellow) stacked on the 3’ G-quartet surface 
(DNA in blue). Sticks and lines (left) and CPK model (right). 
Fig. 4.5-4: DAPER (top) and PIPER5 (bottom) fit both opposite grooves.     
Sticks and lines (left) and CPK model (right). Ligands are yellow 
and DNA blue. 
 
 123 
the positively charged nitrogen atom and the aromatic core. In fact, PIPER6 and PIPER7 
show calculated binding energies close to the ones of PIPER5/DAPER. These two 
compounds have not the nitrogen atom directly linked to the side chain: this means that the 
distance of the nitrogen atom from the aromatic core is roughly the same as in the case of 
PIPER5, that is characterized by a propyl linker (Fig. 4.1.a-1). 
Hydrogen bonds are occasionally formed between the N-H group on the side chains of 
perylene derivatives and several acceptor groups on the DNA, mainly oxygen atoms of the 
phosphate groups (see Fig. 4.5-2/4) and more rarely oxygen atoms on the ribose rings or 
nitrogen atoms on the guanine bases. The number of H-bonds formed per structure increases 
when a positive charge is put on the external nitrogen atom of the piperazine ring of PIPER3 
(EXT, MIX and 2CH forms), because the other N atom (tertiary and not protonated) can act 
as an acceptor group, with the possibility of multiple H-bonds (Fig. 4.5-5). In these cases the 
best binding energy values are reached indeed (Tab. 4.5). 
As for the new perylene and coronene derivatives, CORON shows a strong binding to G-
quadruplex, mainly due to the electrostatic interactions (Tab. 4.5). As deeply discussed in 
chapter 5, it is important to underline that for several reasons it is not correct to compare the 
binding energies obtained for molecules that present a different scaffold. The model reported 
in Fig. 4.5-6 shows that at least two side chains fit into two consecutive grooves, while one or 
both of the others are free to move. The new highly water soluble perylene derivatives show a 
behaviour and binding energies very similar to PIPER and previous perylene derivatives (see 
Tab. 4.5), despite a slight distortion of the aromatic plane due to the presence of the lateral 
rings (Fig. 4.5-7 for PIP-PIPER(1,7)). These compounds were considered protonated only on 
the side chains piperidine rings (on the major axis of perylene). 
Finally, berberine, its analogue coralyne and its derivative piperidin-berberine were 
considered. The models obtained for berberine and piperidin-berberine are reported in Fig. 
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Fig. 4.5-5: multiple H-bonds (red dashed line) formed by PIPER3(EXT).  
Detail coloured according to atom types on the right. 
Fig. 4.5-6: Complex between CORON (yellow) and G-quadruplex 
(blue). Sticks and lines (left) and CPK model (right). 
Fig. 4.5-7: Complex between PIP-PIPER(1,7) (yellow) and G-quadruplex 
(blue). Sticks and lines (left) and CPK model (right). 
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4.5-8 and 4.5-9 respectively. Berberine stacks on the terminal G-tetrad of the G-quadruplex 
structure; the new side chain of piperidin-berberine is suitable to interact with one of the four 
grooves of the G-quadruplex, increasing the binding energy and leading to possible formation 
of H-bonds (Tab. 4.5). 
Although the molecular modeling studies reported here give surely interesting information on 
the molecular features of the complexes between the studied drugs and the parallel 
monomeric G-quadruplex structure, several limitations can be observed in this method, 
mainly related to the absence of explicit water molecules, the rigidity of the DNA structure 
and the strong effect of the positive charges on the ligand molecule. Several attempts 
(described in the following section) have been made to try to solve these problems, but it is 
clear, as discussed in chapter 5, that the binding energy values must not be considered as 
absolute values, but rather as a relative ranking that can be correct only in a series of 
homologue molecules, whose structures are similar.  
 
Further simulations: A first approach in order to better reproduce the real environment in 
which the drug-DNA complexes exist was tried by defining a water-box around the lowest 
energy and most frequently repeated structures, and performing further minimization and 
molecular dynamics, taking into account explicit water molecules. These experiments were 
performed solvating the selected structure from the previous simulated annealing, defining a 
layer of water molecules of 20Å centred on the ligand molecule, through the “soak” function 
inside the InsightII Package. This creates a sphere around the complex of about 1500 water 
molecules, which makes following calculations very slow. First of all, 500 steps of 
minimization of the whole complex according the usual Polak-Ribiere conjugate gradient 
method were performed. Then, a 10ps dynamics at 300K was performed. In this phase, only 
an interface of 7Å from the ligand molecule was completely free to move, while restrains 
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Fig. 4.5-8: Model obtained for the complex between berberine (yellow and atom-
type coloured) and monomeric G-quadruplex (blue). Sticks and lines 
(top left), CPK model (top right) and top view (bottom), that evidences 
the superimposing of the berberine aromatic moiety on the G-tetrad: 
positive charged nitrogen atom is at the centre of the G-tetrad.  
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Fig. 4.5-9: Model obtained for the complex between piperidin-berberine (yellow and 
atom-type coloured) and monomeric G-quadruplex (blue). Sticks and lines 
(top left), CPK model (top right) and top view (bottom). It is evident that the 
position of the new side chain is suitable to interact with one of the four 
grooves of the G-quadruplex. 
 
 128 
were applied to the rest of water molecules to avoid dispersion of the solvation sphere during 
the dynamics. Successively, one frame every 200fs was considered for minimization, so that 
50 structures were minimized. The minimization was performed in three steps: 500 steps of 
PR conjugate gradient on the whole structure, 2000 steps with restraints on all water 
molecules except those belonging to a new defined interface of 8Å from the ligand molecule, 
a final 500 steps of minimization taking fix all the water molecules, so that only the ligand 
molecule was free to move. DNA was fully constrained during the whole process. These 
calculations took a long time and preliminary results on PIPER and DAPER molecules did 
not show significant variations with respect to the models previously obtained, so that they 
were not performed on the other molecules.  
In order to consider flexible DNA, a binding pocket within 5 Å from the ligand in the best 
positions was defined, so that the guanine residues involved in the interactions with drugs 
could be free to move, while so far the DNA has been fully constrained. Different levels of 
tethering were considered during the following simulated annealing, that was identical to the 
second step of the previous simulated annealing. Unfortunately, it was not possible to find a 
value of the tethering parameter suitable for these experiments. If it is too low in fact, no 
change in the final structure was observed. If too high, on the other hand, the movable G-
quartet lose its characteristic H-bonds pattern.  
An analogue problem was found when G-quadruplex structures of different topology or 
duplex DNA structures were taken into account. Also in this case in fact, excessive flexible 
DNA led to improbable structures, while too rigid DNA did not allow ligand molecules to 
interact with DNA bases, in particular terminal G-quartets, since they are not available for 
interactions with drug molecules, as in the case of the open structure used in the previous 
simulations. 
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Finally, an attempt to better calculate charges distribution of ligand molecules, that seems 
such a critical feature, was made by semiempirical calculations with the Mopac module of 
InsightII. The final energy values obtained with this method did not differ from the previous 
ones, calculated with the standard charges distribution according to the CVFF force field.  
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4.6. Preliminary biochemical studies on the new compounds 
 
Preliminary results obtained by PAGE show that berberine and its analogues are able to 
induce G-quadruplex dimeric structures on 2HTR oligonucleotide (Fig. 4.6-1(A)), with a 
different extent (Fig. 4.6-1(B)). Coralyne shows the best efficiency in inducing the G-
quadruplex, in agreement with FRET results (Fig. 4.3.a-3). Furthermore coralyne shows a 
higher telomerase inhibition activity (starting from a concentration above 50µM) than the two 
other compounds, as derived by preliminary TRAP assays, performed using TSG4 as 
substrate, reported in Fig. 4.6-2(A). It is worth noting that while berberine derivatives are able 
to stabilize a preformed G-quadruplex structure at 50mM potassium ions concentration (as 
studied by FRET assay, par. 4.3.a), they are not able to induce an analogue monomeric G-
quadruplex structure at 5mM potassium ions concentration (Fig. 4.6-1(C)). The different 
ability to induce inter and intramolecular G-quadruplex structures was previously observed 
for telomestatin and a porphyrin derivative (Kim et al. 2003); this selectivity was correlated 
with different biological effects of the two compounds.  
In Fig. 4.6-2(B), TRAP assay for CORON is also reported. This compound shows telomerase 
inhibition starting from a concentration of 50µM, similarly to PIPER (Fig. 4.4-1/2). Since the 
two new side chains and the larger aromatic area of CORON, with respect to PIPER, would 
be expected to improve the electrostatic and hydrophobic interactions with G-quadruplex 
DNA, a possible explanation of the moderate inhibitory activity of CORON could relay on 
the influence of the same molecular features on the self-aggregation processes for this new 
molecule. In fact, these processes have been shown to be very important in determining the 
efficiency of the perylene diimides in inducing and stabilizing G-quadruplexes and in 
inhibiting telomerase (chapter 5). In particular, CORON shows a behaviour in aqueous 
solution similar to that of PIPER4 and PIPER5 (Fig. 4.1.a-5). In fact, in the absorption spectra 
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Fig. 4.6-1: A) G-quadruplex structures formation induced on 2HTR oligonucleotide by 
berberine and its derivatives (Fig. 4.1.b-1) studied by native PAGE (PolyAcrylamide 
Gel Electrophoresis) according to the experimental procedure described in par. 3.3.a. 
Experiments were performed at 12 µM oligonucleotide (2HTR) concentration in 
MES-KCl buffer (pH 6.5) at increasing concentrations of the berberine derivatives 
and with no drug (lane 0). In lane P and P3, 2HTR was incubated with 30 µM 
PIPER and PIPER3 respectively. Drugs concentrations: 10 µM (lane 1), 30 µM (2), 
50 µM (3), 70 µM (4) and 100 µM (5). B) Percentage of G-quadruplex structures 
formed (Gq%, see the caption of Fig. 4.2-1) in function of drug concentration (C 
(µM)) relative to the band shift assays reported in A). C) Same as in A) but using 
TSG4 oligonucleotide and a 5mM KCl-10mM MES buffer (pH 6.5).  
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Fig. 4.6-2: A) Inhibition of human telomerase by berberine and its derivatives (Fig. 4.1.b-
1) by Telomerase Repeat Amplification Protocol (TRAP) assay, using TSG4 as 
substrate (par. 3.3.d). In lane 0 no drug was added, in lane R cell extract was not 
added. The considered drugs concentrations were 30 µM (lane 1), 50 µM (2), 70 
µM (3), 100 µM (4) and 130 µM (5). B) TRAP assay on CORON: 10 µM (6), 
20 µM (7), 30 µM (8), 40 µM (9), 50 µM (10)  and 100 µM (11). 
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both at pH 6.5 and at pH 7.5, there is no isobestic point and a strong hypochromic effect with 
respect to the DMSO spectrum can be observed, suggesting the formation of more than one 
type of multimeric aggregates. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 134 
 
 
5. Discussion 
 
Among the different investigated compounds (par. 4.1), perylene diimides with two 
hydrophilic side chains (Fig. 4.1.a-1) have been studied in detail, since they represent a series 
of compounds in which, maintaining unchanged the stacking interactions due to the perylene 
aromatic core, it is possible to compare the effect of different side chains linked to the same 
aromatic moiety (Rossetti et al. 2002, Rossetti et al. 2004). They have been investigated in 
their ability to induce G-quadruplex DNA structures by PAGE method (par. 4.2) and to 
inhibit human telomerase by TRAP assays (par. 4.4). Preliminary results on the stabilization 
of preformed G-quadruplex and duplex DNA structures by one of these compounds by means 
of absorption spectroscopy and circular dichroism are also reported (par. 4.3.b). FRET assays 
(par. 4.3.a/c) have been performed to study the interactions of all the analyzed compounds 
with a pre-annealed G-quadruplex monomeric structure and with a model of duplex DNA. In 
order to elucidate some molecular features of the complexes between the investigated 
compounds and the human monomeric parallel G-quadruplex structure resolved by Neidle 
and coworkers (Parkinson et al. 2002), simulated annealing experiments have been performed 
(par. 4.5). Finally, preliminary results of PAGE and TRAP assays on recently synthesized 
perylene, berberine and coronene derivatives are reported (par. 4.6). 
The results obtained by PAGE measurements of PIPER2 (Fig. 4.2-1) show with good 
evidence that a strong decrease of electrostatic interactions between the drug and DNA does 
not allow the formation of any G-quadruplex structure. Since PIPER2 should be able to 
establish stacking interactions with the G-tetrads, these data confirm the essential role of the 
electrostatic interactions between the side chains of the drugs and DNA grooves. In fact, the 
quaternization of the nitrogen atom on the pyridine ring of PIPER2 (par. 3.1.a) led to the fully 
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charged nitrogen atom of PIPER7, which shows an activity comparable to the best perylene 
derivatives. As for the other perylene diimides, the results reported in this thesis allow to 
establish that both the efficiency in forming G-quadruplex structures, as derived by PAGE 
(par. 4.2), and the telomerase inhibition, as derived by two different TRAP assays (par. 4.4), 
depend on the features of the perylene derivatives side chains. In all cases, a fundamental 
molecular feature appears to be the distance between charged nitrogen atoms in the side 
chains and the aromatic moiety of the drugs. This finding is consistent with the threading 
intercalation model proposed for this kind of molecules by Hurley and coworkers (Fedoroff et 
al. 1998, par. 1.6.a), in which the drug is stacked on the terminal G-tetrad, so that the distance 
defined above is surely of great importance in optimizing the interactions with the phosphates 
in the DNA grooves. In fact, the compounds having the longest distance between the 
positively charged nitrogen atom on the side chains and the aromatic moiety (PIPER3, 
PIPER5, PIPER6 and PIPER7) are the most efficient in inducing dimeric G-quadruplex 
structures at pH 6.5 (Fig. 4.2-1/2). When the distance is shorter (PIPER and PIPER4), a 
different behaviour is observed: PIPER4 is barely efficient in inducing dimeric G-quadruplex 
structures, while PIPER is the only compound able to induce tetrameric G-quadruplex.  
Another important aspect to be considered is the “self-association” of the drugs in water 
solution, probably correlated to the pKa values and the basicity of the side chains, as recently 
reported by Kerwin and coworkers (Kerwin et al. 2002, Kern et al. 2002). The absorption 
spectra of perylene diimides (par. 4.1.a) put in evidence a more complex aggregation for 
morpholine containing perylene derivatives (PIPER4 and PIPER5) with respect to the other 
compounds at pH 6.5. Increasing the pH to 7.5, PIPER behaviour changes, becoming very 
similar to that of PIPER4 and PIPER5. Anyway, the complexity of these processes does not 
allow to find a simple correlation with PAGE results and to develop a structural model. With 
regard to this, it should be noted that as previously suggested by Kerwin et al. (2002), at the 
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moment it is not possible to establish if the binding of the drugs to the G-quadruplex DNA 
occurs from monomeric or aggregated ligands. In the first case, the drug multimerization 
should be competitive with respect to the monomeric drug binding to the G-quadruplex (par. 
1.6.a). 
The length and the basicity of the six perylene derivatives side chains play a synergistic role 
in determining the activity of the drugs.  In fact,  PIPER4 and PIPER5, that have the same 
side chains basicity, result the most inefficient compounds in inducing G-quadruplex 
structures at pH 7.5 (Fig. 4.2-4), evidencing the important role of the drugs self aggregation. 
But it is worth noting that, at pH 6.5, PIPER4 is still the less efficient perylene derivative in 
inducing G-quadruplex structures, while PIPER5, characterized by a longer side chain, results 
so efficient as the other perylene derivatives (Fig. 4.2-2), pointing out an important role also 
for the distance between charged nitrogen atoms in the side chains and the aromatic moiety of 
the drugs. 
According to TRAP assays performed using either TS or TSG4 oligonucleotides as 
telomerase substrate (par. 4.4), PIPER3, PIPER6 and PIPER7 result the most efficient 
perylene derivatives in inhibiting telomerase. A quantitative correlation with PAGE results is 
tempting, but not possible. In fact, in the case of TS, after the synthesis of two telomeric 
repeats the DNA fragments are very similar to the oligonucleotide 2HTR, that was used in the 
electrophoretic mobility shift assays, but the concentrations of telomeric repeats having 
different length can not be evaluated. On the other hand, in the case of TSG4, where the 
sequence is exactly the same used in one of the PAGE assays, the ability of telomerase to 
unfold the G-quadruplex structure formed at the TRAP buffer potassium concentration 
(Gomez et al. 2002) makes difficult to establish a correlation with the behaviour of perylene 
diimides studied by PAGE at different potassium concentrations, but always in the absence of 
the destabilizing effect of telomerase (par. 4.2).  
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Nevertheless, the comparison between the results derived from PAGE (par. 4.2) and 
absorption spectroscopy (par. 4.1.a) in TRAP buffer and those obtained from the two different 
TRAP assays (par. 4.4) allows to establish that the same drugs molecular features which 
determine the G-quadruplex formation strikingly influence also the ability of these 
compounds to inhibit telomerase. In fact PIPER3, PIPER6 and PIPER7 result the most 
efficient perylene derivatives, while PIPER, PIPER4 and PIPER5 appear definitively less 
efficient. These results suggest that a too short side chain and/or a weak basicity of side chain 
amines give rise to a poor inhibitory activity, probably due to the different thermodynamic 
stabilization of the complexes between these drugs and G-quadruplex DNA structures.  
In order to study in depth these thermodynamic aspects, FRET assay on a human monomeric 
G-quadruplex forming sequence has been considered (par. 4.3.a). Although it is not possible 
to use ∆Tm values to access binding affinities when the temperature dependence of binding 
constant has not been first characterized (Canzonetta et al. 2002, Bostock-Smith et al. 1999), 
the results reported for these experiments confirm weaker interactions of PIPER4 and PIPER5 
with monomeric G-quadruplex with respect to the other perylene diimides (Tab. 4.3). The 
compounds that arise most the G-quadruplex melting temperature (PIPER, PIPER3, PIPER6, 
PIPER7) are the same that show the highest efficiency in inducing G-quadruplex structures as 
derived by PAGE (par. 4.2) and in inhibiting telomerase (par. 4.4), with the major exception 
of PIPER, that show a poor telomerase inhibition. These results suggest a good correlation 
between these different techniques. FRET results on CORON show a good efficiency in 
increasing the melting temperature of G-quadruplex DNA, at least comparable to the best 
perylene diimides, while the new perylene derivatives (PIP-PIPER and MORPHO-PIPER) 
show a behaviour similar to PIPER4 and PIPER5. Finally, FRET experiments allowed the 
evaluation of berberine, its analogue coralyne and its derivative piperidine-berberine, 
underlining the improvement of the last compound with respect to berberine itself, due to the 
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new piperidine containing side chain, but also showing the best interactions for coralyne, due 
to its full aromatic core.  
Since the selectivity of G-quadruplex interacting compounds for G-quadruplex DNA with 
respect to duplex DNA is a topic of great interest for the possible biological applications of 
these molecules, preliminary studies using absorption spectroscopy (par. 4.3.b) and FRET 
assays (par. 4.3.c) have been reported. In particular, absorption and circular dichroic spectra 
were registered for PIPER3 in the presence of different concentrations of pre-annealed G-
quadruplexes and calf thymus DNA (par. 4.3.b). The stronger increasing of the molar 
extinction coefficients in the case of quadruplex with respect to duplex DNA suggests a high 
selectivity for this compound. These results and the presence of dichroic bands in the visible 
region indicate that a complete titration in a suitable range of drug/DNA ratios and the 
consequent analysis could be considered a good approach for the evaluation and 
quantification of the interactions between drugs and different DNA structures. FRET assays 
on a fluorescence labelled autocomplementary decamer (par. 4.3.c) suggest a good selectivity 
for G-quadruplex with respect to duplex DNA for all the investigated compounds, with the 
major exception of PIPER7. 
Molecular modeling studies have been performed to elucidate the structural aspects at the 
molecular level in the formation of complexes between monomeric G-quadruplex DNA and 
the analysed compounds (par. 4.5). These studies confirmed the “threading intercalation” 
model proposed for this kind of molecules by Hurley and coworkers (Fedoroff et al. 1998), in 
which the drug is stacked on the terminal G-tetrad, stabilized by pi−pi interactions with the 
central aromatic core, while the side chains interact with the G-quadruplex grooves. For 
perylene diimides two possible orthogonal orientations are possible, while CORON can 
interact simultaneously with the four grooves. As for the series of perylene diimides, the 
energy calculations based on these simulations confirm that the distance between charged 
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nitrogen atoms in the side chains and the aromatic moiety of the drugs is surely of great 
importance in optimising the interactions with the phosphates in the DNA grooves. In fact, the 
compounds in which this distance is longer (PIPER3, PIPER5, PIPER6, PIPER7, DAPER) 
show higher binding energies than the compounds in which this distance is shorter (PIPER, 
PIPER4). The relative ranking obtained for this series of compounds is comparable to their 
efficiency in inducing the monomeric G-quadruplex in TSG4 (par. 4.2) and in inhibiting 
telomerase (par. 4.4), with the major exceptions of PIPER4 and PIPER5. For these molecules 
in fact, the fundamental contribution of the weaker basicity of the morpholine ring is not 
correctly taken into account. This is due to the fact that the simulated annealing method (as all 
the classical docking methods) takes into account only one ligand molecule, that can be fully 
protonated or not protonated. Furthermore, the “self-aggregation” processes are not 
considered. For these reasons, the system is not able to explain the different behaviour of 
PIPER4 and PIPER5, for which the self-aggregation seems much more important than for all 
the other compounds, as suggested by absorption spectroscopy measurements (par. 4.1.a), 
contributing to determine a poor activity both to induce G-quadruplex formation and to inhibit 
telomerase.  
The “threading intercalation” model is also confirmed for the other classes of recently 
synthesized molecules, with the possibility of simultaneous interaction of the four side chains 
of CORON with the four grooves of the G-quadruplex (par. 4.5). It would be tempting to 
compare the binding energies obtained for these molecules to the ones obtained for perylene 
diimides, but this is not correct. In fact, the CVFF force field used in these simulations and, 
similarly, all the other force field available in the InsightII software are not suitable for a 
correct evaluation of the interactions between aromatic systems (Chessari et al. 2002). A more 
complex treatment should be applied, such as the density functional theory (Grimme 2004), 
but this is not possible at the moment in commercially available simple docking softwares. 
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For these reasons, and in any case with the limitations illustrated above and in par. 4.5, a 
comparison between the relative binding energies is correct only in a series of homologous 
molecules, such the perylene diimides. Another important parameter is the amount of total 
charges per molecule, which must be the same for a correct comparison. 
Both these aspects are evident if we consider the three compounds berberine, piperidin-
berberine and coralyne (Fig. 4.1.b-1). They look similar, but they are different exactly for the 
two aspects mentioned above: coralyne has a different aromatic system with respect to the 
other two molecules, while piperidin-berberine has a positive charge more than the other two 
molecules. Piperidin-berberine (with two charges) would be expected to be much more 
efficient in binding to G-quadruplex structure than berberine and coralyne (one positive 
charge per molecule), while these two molecules should not be very different one from the 
other in terms of binding energies (Tab. 4.5). Although it is necessary to be cautious, as 
discussed above, when considering ∆Tm obtained by FRET assays as a parameter to evaluate 
binding affinities, the melting temperatures reported in Fig. 4.3.a-3 suggest a very different 
ranking among these compounds. Coralyne shows melting temperatures much higher than the 
other two compounds, probably due to its full aromatic core, while the new side chain of 
piperidin-berberine increases only slightly the G-quadruplex melting temperature with respect 
to berberine.  
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6. Conclusions and perspectives 
 
The results reported in this thesis show that different molecular features contribute to 
determine the efficiency of G-quadruplex interactive compounds in inducing and stabilizing 
different G-quadruplex structures. In particular, when the pi−pi interactions are the same in a 
series of homologues compounds, which are characterized by the same aromatic core, such as 
perylene diimides, the length and the basicity of the side chains play a main role in 
determining the behaviour of the different compounds. The same molecular parameters 
deeply influence the ability of these compounds to inhibit human telomerase. Molecular 
modeling studies have elucidated some of these experimental results and FRET assays look 
promising as a quick method to evaluate G-quadruplex binding and selectivity with respect to 
duplex DNA. Absorption spectroscopy and circular dichroism will be used to quantify the 
interactions of the studied compounds with duplex and quadruplex DNA structures; the 
reported preliminary results illustrate the potentiality of these methods. PAGE and TRAP 
analysis will be extended to all the recently synthesized new compounds.  
It is worth noting that the synthetic strategies developed to obtain the new perylene and 
coronene derivatives result in a great versatility: different side chains can be added to the new 
coronene moiety, with the possibility of achieving selectivity towards different G-quadruplex 
structures, as has been shown for perylene diimides. Moreover, it is possible to add two 
different kinds of side chains (one type on the imidic nitrogen atoms and a different one 
directly linked to the aromatic moiety), since they are added in two different steps. This is 
very interesting since some G-quadruplex structures have four identical grooves (where the 
side chains mainly interact), while others have grooves of different dimensions. Furthermore, 
by means of intermediate compounds, it will be possible to obtain asymmetric molecules. 
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Finally, the reported berberine analogues and derivatives represent a new interesting class of 
G-quadruplex interacting compounds and telomerase inhibitors, structurally related to natural 
products. 
All the information obtained so far on the interactions between the studied compounds and G-
quadruplexes as well as the techniques used for these studies and the synthetic strategies 
reported in this thesis will be used to design new and more efficient G-quadruplex interactive 
compounds and telomerase inhibitors. 
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Londra e, nel contempo, un motivo di rimpianto al momento della mia partenza. 
 
Infine, un pensiero speciale va a Francesco, il cui gesto tragico e disperato ha rappresentato 
per me insieme momento di dolorosa riflessione, punto di partenza di tanti percorsi ed 
elemento con cui mi sono dovuto costantemente confrontare in questi anni. E in questo 
confronto, soprattutto nei momenti più difficili, ho spesso trovato un motivo per non 
demordere, energia per superare le difficoltà e in ultima analisi, quasi paradossalmente, 
l’amore per quella vita che egli, forse per un solo drammatico momento, ha irrevocabilmente 
disprezzato fino all’estremo. 
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